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ABSTRACT 
 
DEVELOPMENT OF NOVEL COPOLYOXETANES: ANTIMICROBIAL AGENTS 
By Allison Lisa King  
A dissertation submitted in partial fulfillment of the requirement for the degree of 
Doctor of Philosophy, Engineering at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2011 
Major Director: Dr. Kenneth J. Wynne, Professor, Department of Chemical and Life Science 
Engineering 
 
This thesis focuses on solution antimicrobial effectiveness for copolyoxetanes with quaternary 
ammonium and PEG-like side chains. Ring opening copolymerization of                                       
3-((4-bromobutoxy)methyl)-3-methyloxetane (BBOx) and 3-((2-(2-methoxyethoxy) ethoxy) 
methyl)-3-methyloxetane (ME2Ox) yielded random copolymers with 14-100 (m) mole% BBOx 
designated P[(BBOx-m)(ME2Ox)]. Reaction of P[(BBOx-m)(ME2Ox)] with dodecyl 
dimethylamine gave the corresponding quaternary P[(C12-m)(ME2Ox)] polycation salts, 
designated C12-m. Mole ratios and molecular weights were obtained from 
1
H-NMR and end 
group analysis. Differential scanning calorimetry (DSC) studies showed Tg‟s between -69 and -
34 °C. Minimum inhibitory concentrations (MIC) against Staphylococcus aureus, Escherichia 
coli and Pseudomonas aeruginosa showed MIC decreasing with increasing C12 mole% reaching 
a minimum between C12-43 and C12-60. C12-43 had the lowest MIC for all strains. At 5× MIC 
(challenge:10
8 
cfu/ml), C12-43 kills  ≥ 99% of the tested strains within 1 hr. C12-m 
copolyoxetane cytotoxicity toward human red blood cells, HFF (Human Foreskin Fibroblast) and 
HDF (Human Dermal Fibroblast) was low, indicating good prospects for biocompatibility. Cx-m 
 xiv 
 
copolyoxetane antimicrobial efficacy, hemolytic activity and cytotoxicity were further explored 
by changing quaternary alkyl chain length. Copolyoxetanes are represented as Cx-50, where 50 
is the mole percent quaternary repeat units and „x‟ is quaternary alkyl chain length (2 to 16 
carbons). Reaction of P[(BBOx-m)(ME2Ox)] with a series of tertiary amines yielded the desired 
quaternary ammonium segment. DSC studies showed Tg‟s between -40 °C and -60 °C and 
melting endotherms for C14-50 and C16-50. A systematic dependence of alkyl chain length on 
MIC was found with C8-50 being the most effective antimicrobial. Kill kinetics for C8-50 (5× 
MIC, challenge: 10
8
 cfu/ml) effected >99% kill in 1 hour for S. aureus (7 log reduction). C8-50 
efficacy on biomass and cell viability of P. aeruginosa biofilms was investigated. Crystal violet 
(CV) staining assays demonstrate that C8-50 had no effect on adhesion of already established P. 
aeruginosa biofilms, but reduced biofilm formation by killing cells prior to attachment. For anti-
adhesion assays, noticeable reduction in biofilm mass occurred at concentrations greater than 2× 
MIC. Viability studies show a substantial log reduction of 2.1 at MIC. The low cytotoxicity of 
Cx-m copolyoxetanes coupled with low MICs and favorable biofilm results indicate good 
prospects for therapeutic applications. 
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I. Development of Novel Copolyoxetane Antimicrobial Agents 
 
Introduction 
 
 The ongoing threat of antibiotic resistance is an important risk to human health. 
Conventional antibiotics can kill bacteria by hindering their metabolic pathway through cell wall 
synthesis, protein synthesis, or transcription. However, many kinds of bacteria are able to adapt 
and thrive in the presence of antibiotic doses that were once effective. Therefore, there is an 
increased urgency to develop new classes of antimicrobials. The immune systems of a wide 
range of organisms encompass certain polypeptides that afford an ability to protect against 
bacterial infections. These peptides not only are effective against infections, but do so without 
build up of resistance and are referred to as „naturally occurring antimicrobial peptides‟ (AMPs). 
AMPs are believed to function by ionic and hydrophobic interactions with the bacterial 
membrane, causing cell death by altering the phospholipid bilayer, disruption of ion diffusion 
through cell wall ion channels, and affecting changes in the cell potential.[2, 3]  A major advance 
would be attained by developing polycations that mimic the charged/neutral structural chain 
structure of AMPs, but have the potential to be made economically on a large scale. Taking 
guidance from one structural feature of AMPs, the cation/neutral chain structure, the work in this 
thesis will develop amphiphilic copolyoxetane antimicrobials that have the potential to overcome 
bacterial resistance. Encouraging evidence provided in this dissertation shows that these 
antimicrobials are potent against several strains of bacteria in their planktonic states with low 
cytotoxicity to red blood cells (RBCs), Human foreskin fibroblasts (HFFs), and Human Dermal 
Fibroblasts (HDFs). However, when bacteria grow as a biofilm, they are more difficult to treat 
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than their planktonic counterparts. This dissertation also includes the biocidal efficacy of the 
most effective copolyoxetane antimicrobial against P. aeruginosa biofilms. The long term goal is 
to develop an antimicrobial that can be used as a therapeutic agent. 
 
Background and significance: 
 
Antimicrobial resistance and hospital acquired infections. The use of antibiotics in humans, 
animals, and agriculture has played a significant role in the emergence of resistant bacteria. This 
well known development of resistant bacterial strains raises the challenge for development of 
new classes of antimicrobials for which buildup of resistance is curtailed or eliminated.  
 It is reported by the U.S. Center for Disease Control (CDC) that hospital acquired 
infections (HAIs) are among the top ten leading causes of death in the US, costing $20 billion 
annually.[4]  Of these HAIs, 60% involve antibiotic resistant bacteria.[5]   The majority of HAIs 
involve the urinary tract, bloodstream, surgical site, and respiratory tract. Many infections are a 
result of Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa.[6] 
 It should be noted that the resistance of P. aeruginosa has been shown for most 
antimicrobials.[7] Additional lipopolysaccharides and other mechanisms are thought to decrease 
the interaction of antimicrobials with the cell membrane. Among all Gram   (-) bacteria, P. 
aeruginosa has an overall outer cell membrane permeability that is 12-100 times lower than E. 
coli.[8-10] Also, P. aeruginosa has a low susceptibility toward antibiotics as a result of efficient 
efflux pumps.[11] 
 In addition to the acute infections, microbial biofilms are the cause of many persistent 
and chronic infections that are also increasingly difficult to treat and eliminate. For example, 
 3 
 
many patients with Cystic Fibrosis develop chronic lung P. aeruginosa  infections that are very 
complicated to treat with conventional antibiotics because of inherent biofilm formation.[12, 13] 
Biofilms are surface attached bacteria contained within an exopolysaccharide matrix which 
further facilitates the antibiotic resistance associated with these persistent infections.[14] 
 
Bacteria live in Planktonic (free living) and Biofilm states.  Bacteria that are suspended and 
growing in a fluid environment live in a planktonic state while surface attached bacteria exist in a 
biofilm state. Being complex communities of surface and/or cell adhered microorganisms, 
biofilms fundamentally differ from their single celled planktonic counterparts. Biofilms  are 
protected from antimicrobials and the host immune response by an extracellular polymeric 
substance (EPS) matrix comprised of polysaccharides, proteins and/or nucleic acids, which foster 
intercellular adhesion and surface attachment.[14] Biofilm growth occurs in sequential stages 
including i) initial transport of planktonic cells to a surface ii) initial attachment of planktonic 
cells (iii) formation of the EPS and microcolonies (iv) formation of macrocolonies/ biofilm 
maturation and (v) dispersion.[15] Because microbial biofilms are the cause of many persistent 
and chronic infections, they are increasingly difficult to treat and eliminate.  
 P. aeruginosa is one particularly virulent bacterium that can be found to contaminate 
contact lenses and indwelling medical devices like catheters. Its persistence proves catastrophic 
to immunocompromised patients particularly burn patients, cystic fibrosis patients, and the 
elderly. For example, many patients with Cystic Fibrosis develop chronic lung P. aeruginosa 
biofilm infections that are very difficult to eradicate with conventional antibiotics.[12, 13] 
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Antimicrobial Peptides (AMPs) and Synthetic Mimics of Antimicrobial Peptides 
(SMAMPs).  Antimicrobials are 
found in nature, namely a wide 
variety of antimicrobial peptides. 
Zasloff noted that these “naturally 
occurring antimicrobial peptides – 
AMPs” provide the first line of 
defense against bacterial 
infections.[16] The structure of the AMP magainin 1 consists of positively charged segments 
(hydrophilic, blue- circled) and neutral segments (hydrophobic, brown).[17] AMPs have 
relatively low ratios of charged to uncharged units (0.2 for magainins and 0.3 for defensins).[17, 
18]  
  
 These AMPs have a characteristic amphiphilic structure, are water soluble and  
bactericidal at relatively low concentrations.[19-21] Amphiphilic means that they have both a 
hydrophobic and hydrophilic (positively charged units) in the same polypeptide chain. The 
cationic (hydrophilic) portion of the magainin is believed to act as the antimicrobial moiety. 
Because this cationic moiety is attracted to anionic phosphatidyl gylcerol (PG), a component in 
bacterial membranes, it has the ability to differentiate between prokaryotic and eukaryotic 
membranes. The hydrophobic moiety then facilitates bacterial membrane disruption resulting in 
lysing of the cell and eventual cell death as a result of osmotic shock.[2, 3] 
 
 
 
    1 
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Preliminary data from the Wynne Laboratory: P[AB] copolyoxetanes.  
 In pioneering research, Kurt synthesized the first water soluble copolyoxetane 
antimicrobial  that had cation and neutral moieties possessed by naturally occurring antimicrobial 
polypeptides.[22]P[AB] 
copolyoxetanes (2)  are random 
copolymers containing a quaternary      
alkylammonium containing side 
chain „A‟ and an uncharged PEG-
like side chain,  „B‟. Preliminary results showed that these two copolyoxetanes had surprisingly 
good biocidal properties. They are excellent solution antimicrobials with high water solubility 
(up to 400 mg/ml). The good water solubility is due to both the presence of the hydrophilic PEG-
like side chains and the polar quaternary-salt side chains.  
 A major advance would be attained by developing polycations that not only mimic the 
charged/neutral structural chain structure of AMPs, but also have the potential to be made 
economically on a large scale. Chapter 1 of this dissertation explores the synthesis of 
copolyoxetanes by changing the amphiphilic balance. Included in this chapter are the effects of 
these novel copolyoxetanes on antimicrobial activity of planktonic pathogenic bacteria in 
solution and their hemocompatibility. Chapter 2 further explores the effects of these 
antimicrobial copolyoxetanes on human cells. In Chapter 3, the synthesis of AMP-like 
copolyoxetanes with antimicrobial activity in solution is investigated by manipulating the 
quaternary pendant groups. In view of the sensitivity of biocidal potency to amphiphilic balance, 
this optimization of the P[AB] copolyoxetanes is achieved by varying the alkyl chain length 
HO O O
H
A B
m 1-m  
                    2   
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(from C2 to C16) while keeping the mole ratio constant at 50 percent. The copolyoxetanes were 
evaluated for antimicrobial activity and their effects on human cells. Chapter 4 addresses the 
effect of the most potent antimicrobial copolyoxetane on P. aeruginosa biofilms. 
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Chapter 1 
Highly Effective, Water Soluble, Hemocompatible Poly[(3,3-Quaternary/PEG)-
Copolyoxetanes] 
 
ABSTRACT 
 This study focuses on the solution antimicrobial effectiveness of a novel class of 
copolyoxetanes with quaternary ammonium and PEG-like side chains. A precursor P[(BBOx-
m)(ME2Ox] copolyoxetane was prepared by cationic ring opening copolymerization of 3-((4-
bromobutoxy)methyl)-3-methyloxetane (BBOx) and 3-((2-(2-methoxyethoxy)ethoxy)methyl)-3-
methyloxetane (ME2Ox) to give random copolymers with 14-100 (m) mole% BBOx. Reaction 
of P[(BBOx-m)(ME2Ox)] with dodecyl dimethylamine gave the corresponding quaternary 
P[(C12-m)(ME2Ox)] polycation salts, designated C12-m, as viscous liquids in 100% yield. 
BBOx:ME2Ox and C12:ME2Ox ratios were obtained by 
1
H-NMR spectroscopy. C12-m 
molecular weights (Mn, 3.5-21.9 kDa) were obtained from 
1
H-NMR end group analysis. DSC 
studies up to 150 °C showed only thermal transitions between -69 and -34 °C assigned to Tg‟s. 
Antibacterial activity for the C12-m copolyoxetanes was tested by determining minimum 
inhibitory concentrations (MIC) against Gram(+) S. aureus and Gram(-) E. coli and P. 
aeruginosa. MIC decreased with increasing C12 mole percent, reaching a minimum in the range 
C12-43 to C12-60. Overall, the antimicrobial with consistently low MICs for the three tested 
pathogenic bacteria was C12-43: (bacteria, MIC, μg/ml) E. coli (6), S. aureus (5) and P. 
aeruginosa (33). For C12-43, minimum biocidal concentration (MBC) to reach 99.99% kill in 24 
hr required 1.5 times MIC for S. aureus and 2 times MIC for E. coli and P. aeruginosa. At 5× 
MIC against a challenge of 10
8
 cfu/ml, C12-43 kills ≥ 99% S. aureus, E. coli and P. aeruginosa 
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within 1 hr. C12-m copolyoxetane cytotoxicity toward human red blood cells was low indicating 
good prospects for biocompatibility. The tunability of C12-m copolyoxetane compositions, 
effective antimicrobial behavior against Gram(+) and Gram(-) bacteria, and promising 
biocompatibility offer opportunities for further modification and potential applications as 
therapeutic agents.  
 
Introduction 
 
Aqueous solutions of alkylammoniums have long been employed as antimicrobials.[23-
25] In 1984, Ikeda noted that “The adsorption of polycations onto the negatively charged cell 
surface is expected to take place to a greater extent than that of monomeric cations because of 
the much higher charge density carried by the polycations.”[26] Subsequent research from the 
Ikeda laboratory explored antimicrobial activity for a number of polycation architectures and 
compositions.[27-30] The last decade has seen a substantial growth in interest in polycation 
antimicrobials. Homopolycations,[31-34] copolymers,[35-37] and molecular polyamines        
[38, 39] have been explored. 
 
Several polycation chain architectures have been shown more effective than their 
respective low molar mass analogs including side chain polyacrylates with biguanide groups[26, 
28] and polyphosphonium salts with alkyl side chains.[30, 40, 41] Polycationic dendrimers are 
also effective antimicrobials.[42, 43] Recent studies have included the development of 
amphiphilic polycations designated AP which, although very different in terms of molecular 
structure,[3, 44, 45] are intended to mimic the charged / neutral repeat unit combination of 
 9 
 
naturally occurring antimicrobial polypeptides (AMPS).[19, 38, 46] AP have also been 
designated as SMAMPs, synthetic mimics of antimicrobial peptides.[47] 
 
Reflecting the wide diversity of polycations, cholic acid derivatives were developed by 
Savage to mimic the bactericidal behavior of polymyxin B (PMB).[48]  The cationic lipopeptide 
PMB is used as a “last resort for the treatment of serious Gram-negative infections caused by 
multiresistant strains.”[49] The structure of one of the synthetic cholic acid polycations (CSA-
13) is shown in Table 1.1(16).  
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Table 1.1. Selected polycation structures and MICs (µg/ml, µM). For a given structural class, structures (and MICs) are for an                   
optimum representative composition. 
 
Polycation Structure Notes Bacteria MIC 
µg/ml, 
(µM) 
Reference 
  4  
O S
H
O
O
N
O
Cl
7
 
Methacrylate 
homopolymers and 
copolymers with a 
quaternary amine 
functionalized side 
group; optimum 
quat composition 
shown; higher 
DPs, lower MICs 
  
- E. coli >2000 
µg/ml 
(>870 µM) 
   
[36] 
  5        
Homopolymers of 
acrylate monomers 
with biguanide 
groups. 12.1 kDa. 
- E. coli 
 
 
 
- S. aureus 
 
 
 
- P. 
aeruginosa 
- 660-1000 
µg/ml (55 - 
83 µM) 
 
- 100-330 
µg/ml (8.4-       
27 µM) 
 
- 660-1000 
µg/ml (55 - 
83 µM) 
[26] 
 11 
 
N CH3
O
S
O
O
O
HN
O
O
N
O
N 11
24
 
 
 
6 
Poly(2-methyl-1,3-
oxazoline) with 
terminal 
quaternary 
ammonium groups; 
optimum quat 
composition; 
higher DPs, lower 
MICs. 
. 
 
 
 
- S. aureus 200 µg/ml 
(74 µM) 
[37] 
 7    
O
CH3
O
OO
N
R
Cl
n
 
Methacrylate 
polymers with 
pendant quaternary 
ammonium groups, 
Mn = 32.5 kDa 
 
 
 
- E. coli 
 
 
- S. aureus 
 
 
 
 
 
- E. coli 
 
- S. aureus 
- R =  
-C12H25, 
64 µg/ml 
(2 µM) 
128 µg/ml 
(4 µM) 
n = 70 
 
- R =  
-C16H33 , 
256 µg/ml 
(8 µM) 
32 µg/ml 
(1 µM) 
[33] 
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 8    
N
R
O O
CH3
I
n n
 
Pyridinium 
methacrylate 
copolymers 
 
- E. coli 
 
 
 
 
- B. subtilis 
- R = 
-C4H9, 
50 µg/ml 
(2.2 µM) 
 
- R =  
-C6H13, 
30 µg/ml 
(1.1 µM) 
n = 50 
[50] 
   9   
O S
O
O
N
O
(CH2)3CH3
OO
0.63 0.37
9
H
Cl
 
Methacrylate 
copolymers with 
butyl side groups 
(quaternary amine 
functionalized) 
 
 
- E. coli 34 µg/ml, 
(14 µM) 
 
 
[36] 
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10  
Amphiphilic 
polynorbornene 
derivatives 
 
 
- E. coli 
 
 
- B. subtilis 
- 25 µg/ml 
(2.5 µM) 
 
- 25 µg/ml 
(2.5 µM) 
 
 
[34] 
11 NH3Cl
20
 
Facially 
amphiphilic 
poly(m-phenylene 
ethynylene) 
polymers 
 
 
 
- E. coli 
 
 
 
- B. subtilis 
- 25 µg/ml 
(4.6 µM) 
 
 
- 25 µg/ml 
(4.6 µM) 
 
 
[32] 
 
12 
PEGylated – 
quaternary acrylate 
copolymers  
- B. subtilis 
 
q = 1 
(methyl) 
- 20 µg/ml 
(1.02 µM) 
[51] 
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13 
N N
H
O
O
NH2
NH2
H
Cl
H
5  
Oligoguanidines 
 
 
- E. coli 
  
 
- S. aureus 
- 8 µg/ml 
(9.5 µM) 
 
- 4 µg/ml 
(4.7 µM) 
 
  
[31] 
C12-43  
C12-43 
Mn = 2.5 kDa 
 
 
- E. coli  
 
- S. aureus 
 
- P. 
aeruginosa 
- 6 µg/ml 
(2.4 µM) 
- 5 µg/ml 
(2 µM) 
- 33 µg/ml 
(13 µM)  
Present 
study 
14
N
O
O O
N
R
CH2PhHC
Br
7
 
Polyoxanorbornene 
with alkyl 
pyridinium side 
chains 
 
R = octyl group 
- E. coli 
 
 
 
- B. subtilis  
- 4 µg/ml 
(1.3 µM) 
 
 
- 4 µg/ml 
(1.3 µM) 
 
 
 
[52] 
15 
O S
H
O
O
NH
O
(CH2)3CH3
OO
0.77
Cl
0.23
9
 
Butyl methacrylate 
-tertiary amine 
methacrylate 
copolymers 
- E. coli 3.8 µg/ml 
(2.4 µM) 
 
 
[36] 
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16 
N NH
N
S
NH3  Cl
H2N
H
N
S
NH2
O O
NH3  Cl
 
Dication with a 
4,6-dicarboxy 
pyrimidine core 
- E. coli 
 
 
 
- B. subtilis 
- 0.8 µg/ml 
(1.2 µM)  
 
 
- 0.8 µg/ml 
(1.2 µM) 
[39] 
NH2OOH2N
N
H
O
H2N
H H
 
 
17 
CSA-13 
Ceragenin 
- S. aureus 
(vancomycin 
resistant)     
- 1 µg/ml 
(1.5 µM) 
[1, 38] 
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In antimicrobial studies, the minimum inhibitory concentration (MIC) is the 
concentration at which bacterial growth is inhibited in nutrient media. The minimum bactericidal 
concentration (MBC) is the concentration at which all bacteria are killed. Because bacteria have 
sizes larger than the wavelength of visible light, determining whether bacteria grow is 
conveniently measured by UV-visible spectroscopy. Growth after 24 hr is signaled by turbidity 
that results in absorption at 600 nm.[34, 36] At short test times kill kinetics vary substantially 
depending on the biocide, its concentration, and bacterial target. From the few studies carried out 
on polycation kill kinetics[26, 38] concentrations 5 or 10 times higher than MICs are necessary 
to achieve rapid kill. If rapid kill is required, low MICs are desirable for economy and to avoid 
high antimicrobial concentrations that could lead to adverse effects on human cells. 
 
In addition to low MICs, an important feature emerging from recent studies of 
amphiphilic polycation antimicrobials is that, at least in some cases, bacteria fail to develop 
resistance.  For example, poly(4-N-alkylpyridinium salts) were still active against S. aureus 
strains that developed resistance to N-hexylpyridinium bromide.[53] Failure to develop 
resistance may not be a universal characteristic of amphiphilic polycations. Hancock reported 
that sub-inhibitory levels of polycationic antibiotics such as polymyxins induce resistance toward 
higher, otherwise lethal, levels of these antimicrobial agents.[54]  
By analogy to antimicrobial peptides, the killing mechanism for polycations is explained 
by a combination of ionic and hydrophobic interactions between the bacterial cellular membrane 
and multiple ammonium moieties.[27] After or coincident with polycation chemisorption, 
disruption of the phospholipid bilayer includes diffusion through the cell wall. Polycation 
diffusion and binding to the cytoplasmic membrane leads to further changes resulting in cell 
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death. This mechanism was described by Ikeda in the early 1980‟s.[26-28] Subsequently, many 
researchers provided additional details and insights with regard to this mechanism.[38, 55] 
  
Ikeda noted the greater release of K
+
 for polycations compared to a single-charge 
quaternary.[27, 28] With singly charged ammonium species, one mole of K
+
 salt may be released 
from the bacterium [B(nK
+
)nX
-
] per mole of ammonium (Eq. 1). For polycations the number of 
moles of K
+
 salt released can be as great as the number of charges m per polycation. Eq. 2 
illustrates a molecular polycation with m charges releasing m x n equivalents of K
+
. 
 
B(nK
+
)nX
-
    +     nA
+
Y
-
     B (nA+)nX-    +    nK+Y-                      Eq. 1 
B(nK
+
)nX
-
    +     AP
m+
(mY
-
)     B(AP(m x n)+)Xn-     +    (m x n) K
+
Y
-
   Eq. 2 
 
Polycation effectiveness (PE) can be understood in terms of the entropic driving force 
generated by polycations binding to bacteria with release of potassium salt (Eq. 2). Potassium ion 
release disrupts the bacterial cell potential contributing to cell death. While providing a partial 
explanation for polycation effectiveness, the broad range of polycation activity, ranging from 
negligible to powerful reflects other important considerations such as amphiphilic balance and 
polycation architecture, the nature of which are not yet well understood. 
 
Previously, we reported the 
incorporation of polycation copolyoxetane soft 
blocks into polyurethane coatings and examined 
HO O
m
O
CH2
N
C
H2
Br
-
+
4
O
1-m
OCH2CH2
OCH3
2
H
H
12
   1 
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contact antimicrobial properties.[56] One of the precursors to new soft blocks employed in this 
coatings effort was 1 with 14 mole percent quaternary bromide (C12-14). The previously 
reported HMDI/BD(30)-P[(C12-14)(ME2Ox)-8900], is designated C12-14-PU, where the hard 
block (30 wt %) was derived from 4,4‟-(methylene bis(p-cyclohexyl isocyanate) (HMDI) and 
butanediol (BD). Highly effective contact kill (not biocide release) was demonstrated for neat 
C12-14-PU coatings and for a blend of C12-14-PU with a base polyurethane.[56]  As a polymer 
surface modifier, only 2 wt% C12-14-PU added to a conventional polyurethane resulted in a 
coating that provided 100% kill in 30 min exposure to spray challenges (~10
7
 cfu/ml) of E. coli 
or P. aeruginosa and 98.7% kill for S. aureus.[56]  
 
Aqueous solubility for C12-14 (1, m = 0.14), a random copolyoxetane generated by 
simultaneous addition of comonomers,[57-59] raised interest in investigating solution 
antimicrobial properties for C12-m copolyoxetanes.  To initiate this investigation a series of 
water soluble C12-m copolyoxetanes was prepared with increasing C12 mole percent. Minimum 
inhibitory concentrations (MICs) were determined for three bacterial pathogens including Gram 
(+) S. aureus and Gram (-) E. coli and P. aeruginosa. With optimum compositions, MICs as low 
as 5 μg/ml were observed. Kill kinetics and MBCs were determined for C12-43, one of the most 
highly effective C12-m copolyoxetanes. Low cytotoxicity toward human red blood cells 
indicated good prospects for biocompatibility of C12-m copolyoxetanes. Interestingly, selectivity 
for antimicrobial behavior against Gram(+) S. aureus and Gram(-) E. coli was dependent on the 
mol % C12. For high mol% C12, selectivity was opposite that previously reported. 
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Experimental 
Materials.  3-Bromomethyl-3-methyloxetane (BrOx) was generously provided by OMNOVA 
Solutions (Akron, OH). N,N-dimethyldodecylamine (C12) was a gift from Lonza (Allendale, 
NJ). Methylene chloride (CH2Cl2), and tetrahydrofuran (THF) were obtained from Aldrich and 
dried by storing over 4Å molecular sieves. Boron trifluoride etherate (BF3O(C2H5)2), 
tetrabutylammonium bromide (TBAB), dodecyltrimethyl ammonium bromide (DTAB), 3-
(hydroxymethyl)-3-methyloxetane, 1,4-dibromobutane and sodium hydride (NaH) were also 
obtained from Aldrich and used as received. 1,4-Butanediol (BD) and 2-(2-
methoxyethoxy)ethanol were purchased from Acros Chemicals and used as received. All M9 
media components[60] were purchased from Sigma Aldrich. Luria Broth (LB) was purchased 
from Fisher Scientific. Human red blood cells (RBCs) were obtained from Innovative Research 
(Novi, MI) packed and transported on ice in a cooler (~ 4 °C), refrigerated upon receipt and used 
within one week. 
 
Designations. As noted above, P[(C12)m(ME2Ox)1-m] copolyoxetanes 1 are designated by 
C12-m, where m is the mole percent C12-containing repeat unit. Similarly, BBOx-m is used to 
represent the mole percent BBOx in the P[(BBOx)m(ME2Ox)1-m] copolyoxetane precursor.  
 
Synthesis and Characterization. Monomers were synthesized as described previously.[22] 3-
((4-Bromobutoxy)methyl)-3-methyloxetane (BBOx) and 3-((2-(2-
methoxyethoxy)ethoxy)methyl)-3-methyloxetane (ME2Ox) monomers were distilled prior to use 
(BBOx: 85 
o
C/5 mmHg, ME2Ox: 100 
o
C/5mmHg). Minimum monomer purity was typically 99+ 
percent (GC-MS). Monomer synthesis and purification was followed by a ring opening 
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polymerization to BBOx-m copolyoxetane precursors as described by Kurt.[22] Reaction with 
C12 tertiary amine gave C12-m copolyoxetanes 1. As an example, the preparation of BBOx-42 
and the corresponding C12-43 is provided below. 
 
P[(BBOx)0.42(ME2Ox)0.58], BBOx-42.   Through a metering pump, over a period of 3 hr under 
nitrogen purge, a solution of BBOx (5.74 g, 24.2 mmol) and ME2Ox (10 g, 49 mmol) in  30 mL 
anhydrous CH2Cl2 was added to a three-necked 100 ml flask containing BF3OEt2,  1,4-
butanediol (0.06 g, 0.67 mmol)  and 25 ml anhydrous CH2Cl2. The reaction system was stirred 
for 15 hr at 0 
o
C. The mixture was quenched with H2O followed by stirring for 0.5 hr. The 
organic phase was washed in sequence with 3 wt% aqueous HCl, 3 wt% aqueous NaCl, and two 
times with 20 ml distilled water. The solvent was evaporated and the residue was dried at 80
 o
C 
under vacuum for 48 hours to obtain 15.8 g BBOx-42 copolymer. 
1
H-NMR (CDCl3:  0.91 ppm 
(-CH3, 3H,s), 1.68 ppm (side chain –OCH2CH2CH2CH2Br, –CH2-for BBOx,  2H), 1.92 ppm 
(-OCH2CH2CH2CH2Br, –CH2-for BBOx,  2H),   3.19 ppm (main chain –CH2-, 4H,m), δ3.30 
ppm (-CH2, 2H, s), 3.38 ppm (-OCH3 3H, s), 3.4 ppm (-CH2Br-, 2H), 3.55 ppm (-OCH2CH2O-, 
4H, m), 3.64 ppm (-OCH2CH2O-, 4H, m).  
The preparative procedure was the same for other BBOx-m copolyoxetane precursors, 
but the amount of the comonomers, catalyst and the co-catalyst was changed to obtain desired 
copolymer compositions shown in Table 1.2. The value of „m‟ for the BBOx-m copolyoxetane 
intermediates and C12-m was determined by 
1
H-NMR spectroscopy as described in Appendix A. 
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Table 1.2. Reactants for BBOx-m synthesis and copolyoxetane compositions. 
 
BF3 etherate 
catalyst 
 g (mmol)
a
  
BBOx feed 
 g (mmol) 
ME2Ox feed 
g (mmol) 
BBOx/ME2Ox 
molar feed ratio 
BBOx:ME2Ox 
mole ratio 
b
 
BBOx:ME2Ox 
mole %
b
 
Mn 
kDa
c 
1.83 (12.9) 3.82 (16.1) 23.08 (113) 1:7 1:6 14:86 7.8 
 
0.147 (1.04) 3.20 (13.5) 8.27 (40.5) 1:3 1:3 25:75 5.9 
 
0.185 (1.31) 5.74 (24.2) 10.0 (49.0) 1:2 1:1.4 42:58 2.5 
 
1.69 (12) 9.5 (40.9) 10.0 (49.0) 1:1.22 1:1 50:50 5.7 
 
0.77 (5.44) 7.1 (30) 5 (24.5) 1.22:1 1.5:1 60:40 11.5 
 
0.24 (1.69) 7.5 (31.6) 2.15 (10.5) 3:1 6.7:1 87:13 12.2 
 
0.24 (1.69) 10 (42.2) 0 NA
d 
NA
d 
100:0
e 
6 
 
a. The mole ratio of catalyst (BF3) to co-catalyst (butane diol) was 2:1. 
b. The BBOx and ME2Ox mole percents were determined by 
1
H-NMR integration.   
c. Mn was determined by end group analysis employing 
1
H-NMR. 
d. NA = not applicable 
e. P[BBOx] 
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P[(C12)m(ME2Ox)1-m] copolyoxetanes, C12-m. BBOx-m copolyoxetanes were quaternized with 
N, N-dimethyldodecylamine to yield the C12-m analogs. Table 1.3 provides reactant quantities. 
An example follows for C12-43, that is P[(C12)0.43(ME2Ox)0.57]. Copolyoxetane BBOx-42  (4 g, 
1.6 mmol) in 20 ml acetonitrile was heated to reflux and N, N-dimethyldodecylamine (6.14g, 
28.9 mmol) was added slowly. The mixture was stirred for 15 hours under nitrogen. The solvent 
and excess N, N-dimethyl dodecylamine were evaporated under vacuum to yield a highly 
viscous, slightly yellow liquid. 
1
H-NMR (CDCl3):  0.82 ppm (-CH3, 6H,s), 1.2~1.4 
(-CH2(CH2)10CH3, 20H), 1.68-1.92  ppm (-OCH2CH2CH2CH2N-,  4H, broad),  3.19 ppm (main 
chain –CH2-, 6H, m), 3.30 ppm (-CH2, 2H, s), 3.38 ppm (-OCH3 3H, s), 3.4 ppm (-CH2N- 2H, 
CH3-N-CH3,6H), 3.55 ppm (-OCH2CH2O-, 4H, m), 3.64 ppm (-OCH2CH2O-, 4H, m). 
 
Figure A1 shows the 
1
H-NMR spectrum and assignments for BBOx-42 and C12-43. 
1
H-
NMR spectroscopy was used to establish that substitution of C-Br by the amine was complete. 
The calculations and methods used for confirming the molar ratios are described in Appendix A. 
The different compositional designations (BBOx-42, C12-43) result from round-off of slightly 
different 
1
H-NMR integrations. Molecular weights (Mn) for BBOx-m copolyoxetanes were 
determined by 
1
H-NMR end group analysis (Tables 1.2 and 1.3).[57] C12-m copolyoxetane 
molecular weights (Mn) were calculated based on those for BBOx-m precursors (Table 1.3). 
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Table 1.3. Reactants for quaternization and C12-m copolyoxetane Tg.  
 
 
a.  Ratio of C12 to ME2Ox repeats obtained from 
1
H-NMR integration (details in Appendix A Information). 
b.  Calculations pertaining to reconfirmation of the degree of substitution of the BBOx-m copolyoxetane precursor is 
     explained in the Appendix A.  
 
 
BBOx/ME2Ox 
Mole % ratio 
BBOx-m, g (mmol) C12   
g (mmol) 
C12:ME2Ox
a
 
Mole ratio(mole 
%) 
C12-m 
Mn, kDa  
Tg (°C) 
14:86 9.41 (1.81) 1.83 (8.6) 0.16 (14:86) 8.9 -69 
25:75 3.95 (0.67) 2.03 (9.54) 0.35 (26:74) 7.4 -67 
43:58 4.00 (1.6) 6.14 (28.9) 0.74 (43:57) 3.5 -57 
50:50 3.00 (0.52) 4 (0.014) 0.99 (50:50) 8.4 -56 
60:40 1.94 (0.17) 3.00 (14.1) 1.5 (60:40) 18 -53 
87:13 3.29 (0.27) 5.27 (24.8) 6.3 (87:13) 21.9 -34 
100:0 2.2 (0.37) 5.38 (25.3) R.H.S = 0.3
b 
L.H.S = 0.31 
11.4 -47 
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GPC. GPC for C12-60 and C12-87, two representative C12-m copolyoxetanes, was obtained 
using a Viscotek Model 302 with refractive index, light scattering and viscosity detectors. With 
THF as the mobile phase and columns for polar polymers (GRAM1000A and GRAM30A, PSS-
USA) no signals were obtained suggesting polycation chemisorption on the columns. GPC was 
tried using acetic acid/water (5:95) as mobile phase[61] with GPC columns recommended for 
polycations (Viscotek C-series C-MBMMW-3078). Once again, the lack of signals for all 
detectors indicated column chemisorption. Chemisorption of dendrimer polycations precluded 
molecular weight determinations by Cooper.[42, 43] 
 
Prior studies used sodium nitrate[62, 63] or other salts and/or buffer solutions[64-68] to 
adjust ionic strength and prevent aggregation. However, precipitation for C12-60 and C12-87 
was observed in the presence of various aqueous salts at several concentrations (0.1 to 1.0 M). 
As noted below, insolubility in the presence of salts also required the development of special 
growth media for solution antimicrobial tests. GPC results were finally obtained with pure water 
as the mobile phase (ViscoGel Polycationic C-MBMMW-3078 column) using a 65 kDa Dextran 
standard. PEO standards gave irreproducible results with this column. GPC Mn (PD) for C12-60 
and C12-87 were 8.2 kDa (4.6) and 20.5 kDa. (1.9), respectively.  
 
Instrumentation: 
1
H-NMR characterization was done using a Varian Mercury 300 MHz NMR 
spectrometer, FTIR spectra were obtained with a Magna-IR 760 spectrometer, and Modulated 
Differential Scanning Calorimetry (MDSC) utilized a DSC Q1000 (TA Instruments). A Perkin-
Elmer GC-MS, model G1530A was used for assessing monomer purity.  
 
 25 
 
Antimicrobial Assay: Minimum Inhibitory Concentration (MIC):  
 
Bacterial suspension preparation. Strains of Escherichia coli (EC) DH5α, Pseudomonas 
aeruginosa (PA) PA01 and Staphylococcus aureus (SA) ATCC-25904 were used for the biocidal 
tests.  The cultures were streaked on Luria Agar plates and incubated overnight at 37 ºC. A single 
colony from each strain was used to inoculate 6 ml of Luria Broth (LB), and grown overnight at 
37 ºC with vigorous shaking (225 rpm). A stock solution of (10
8
 – 109) colony forming units per 
milliliter (cfu/ml) of the desired bacteria was prepared from the bacterial solution in steady 
phase.  
 
MIC medium. Initially Luria Broth (LB) was used as the medium for MIC evaluation of 
monovalent alkylammonium bromide DTAB. However, the C12-m copolyoxetanes precipitated 
in LB. Different media formulations were tested that would prevent polycation precipitation and 
at the same time generate substantial bacterial growth during the 24-hr incubation period. M9 
growth medium was prepared containing 20 wt% mannitol as the source of carbon for EC and 
PA. However, significant growth for SA was not observed. A modified Tryptic Soy Broth (TSB) 
was chosen for MIC evaluation of SA as good growth was observed. Table A1. and Table A2. 
shows the ingredients used in preparing the respective media. 
 
MIC Assay. MIC values for C12-m copolyoxetanes were determined by standard methods.[34, 
36, 69] Stock solutions were made by dissolving different concentrations of C12-m 
copolyoxetanes in distilled water. The medium (6 ml, 1X mannitol for EC and PA or TSB for 
SA) were placed into Erlenmeyer flasks. Serial dilutions of C12-m copolyoxetane stock solutions 
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and 60 µL of the bacterial cultures (~ 10
8
 cfu/ml) were added sequentially to the flasks. The 
flasks were then kept in shakers at 37 ºC for 24 hours. Bacterial growth was examined by 
measuring solution optical density (Beckman Coulter DU 640 UV-Visible spectrophotometer, λ 
= 600 nm) in addition to noting visual turbidity (Figure A3). This MIC assay, which depends on 
a change in optical density of two orders of magnitude and a visual observation of solution 
transparency, provides confirmation of complete inhibition, that is, MIC100.[34, 36, 70] 
To determine the efficiency of polyvalency, the MIC values were normalized to MIC per 
quaternary charge bearing repeat unit. An illustration for the above conversion is given in 
Appendix A-3.  
 
MBC Assay. Bacterial suspensions were prepared as described above. C12-43 was selected for 
MBC assay as overall this was one of the most effective antimicrobial composition. MIC tests 
were performed at different C12-43 concentrations (0, 1.5, 2 and 3× MIC). After 24 hr, a 1 ml 
aliquot from each of the flasks was taken and centrifuged at 1400 rpm for 3 minutes. The 
supernatant formed in this process was gently removed and the pellet was resuspended in 1 ml of 
saline. This process was repeated 2 times and 100 µl aliquots were taken and then plated on agar 
plates in triplicate. The plates were incubated at 37 ºC for 24 hrs. The number of colonies on 
each plate was read and MBC for C12-43 was determined.  
 
Killing Kinetics Assay. Agar plates were streaked with either E. coli, P. aeruginosa, or S. aureus 
from a frozen stock culture at -70 
o
C and incubated at 37 
o
C for 18-24 hrs. From this plate, a 
single colony was collected and used to inoculate 6 ml of Luria broth. This culture solution was 
incubated for 18-24 hrs at 37 
o
C. A subculture was made by preparing a 1:100 dilution in LB and 
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incubated at 37 ºC until it reached an optical density of ~ 0.5 by UV-VIS (logarithmic growth 
phase). A 20 ml aliquot of this bacterial culture was taken and spun down to a pellet for 10 min 
at 10,000 rpm in an ultracentrifuge. The supernatant was discarded and the pellet was dissolved 
in 20 ml of the respective growth media used for the MIC tests (1X mannitol for E. coli, P. 
aeruginosa, or TSB for S. aureus). The bacterial culture was divided into two equal volumes; 
one served as the control, while C12-m copolyoxetane was added to the other at the desired 
concentration. At selected times (t = 0, 1 hr, 2 hr, 3 hr), 1 ml aliquots were taken from both the 
control and sample flasks and spun into a pellet in a microcentrifuge for 3 minutes at 1400 rpm. 
The supernatant was discarded and the pellet was resuspended in saline solution. The same cycle 
was repeated twice so that the pellet suspended in saline contained no growth media. A serial 
dilution series was performed with 100 µL of the bacterial culture in saline. 100 µL aliquots 
were taken from each dilution and plated on Luria agar plates. These plates were incubated at 37 
ºC for 24 hours. The number of colonies were counted and compared with the control to obtain 
percent kill as a function of time.  
 
Cell Cytotoxicity Assay: HC50 protocol. The hemolytic toxicity assay followed the procedure 
described by Palermo and Kuroda.[36] RBCs (1ml) were diluted with 9 ml of phosphate buffered 
saline, PBS, (i.e. 10mM phosphate, 138 mM NaCl, pH 7.4, Sigma) and then centrifuged at 1000 
rpm for 5 min. The resulting supernatant was removed using a pipette making sure not to disturb 
the RBCs and these steps were repeated two more times. The assay stock (90 µL) was mixed 
with each of the polymer solutions (10 µL) on a sterile 96 well round bottom polystyrene 
microplate to give a final solution of 3.3% v/v RBC. Based on a hemacytometer count, this was 
approximately 10
8 
red blood cells per mL. PBS (10 µL) or Triton X-100 (10 µL, 1% v/v) was 
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added to the assay stock solution as negative and positive hemolysis controls, respectively. 
Triton X-100, a non-ionic surfactant is commonly used as a positive control in hemolysis 
assays.[36] For C12-m copolyoxetanes tests, 10 µL of stock solutions were added. The 96 well 
microplate was secured in an orbital shaker at 37 °C and 250 rpm for 1 hr and then centrifuged at 
1000 rpm for 10 min. The resulting supernatant (10 µL) from each well was transferred to a new 
sterile 96 well round bottom polystyrene microplate and diluted with PBS (90 µL). 
Absorbance at 405 nm, characteristic of cell lysis,[36] was determined using a Versamax EXT 
microplate reader (Molecular Devices, Sunnyvale, CA). Negligible absorbance was observed for 
the negative control (PBS) while the absorbance for the positive control (Triton X) was 3.9. The 
fraction of hemolysis is defined as the absorbance for C12-m treated wells divided by the 
average of readings from the positive control wells.  Percent RBC hemolysis is plotted as a 
function of C12-m copolyoxetane concentration in Figure 1.5. Two separate trials were carried 
out in triplicate for each assay trial. Values reported are the average of the two trials.  
 
Results  
 The structure and compositions of C12-m copolyoxetanes 1, designated by mole percent 
C12 (e.g., C12-43), are first discussed followed by minimum inhibitory concentrations (MICs) 
and kill kinetics. The effect of polyvalency was examined by comparing MICs for 1 against 
Gram +/- bacteria versus those for dodecyltrimethyl ammonium bromide (DTAB). DTAB does 
not bear a PEG function, but it is a quaternary salt that was chosen as a monocation reference. 
Linear charge density, that is, C12 mole percent was systematically increased so as to observe 
trends and/optimum compositions. The results for C12-m copolyoxetanes are compared with 
related amphiphilic polycation systems.  
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P[(C12-m)(ME2Ox)-MW] copolyoxetanes. Copolyoxetanes 1 with 14, 26, 43, 50, 60, 87, and 
100 mole % C12 were prepared in two steps. The ring opening copolymerization via 
simultaneous addition of 2 and 3 provided P[(BBOx)m(ME2Ox)1-m] (BBOx-m) copolyoxetane 
intermediates. The monomer feed, feed ratio, experimentally determined compositions, and Mn 
for each of the six copolyoxetane precursors are in Table 1.2. BBOx/ME2Ox mole ratios were 
determined by integrating 
1
H-NMR spectra (Experimental / Appendix A). GPC on the C12-m 
copolyoxetanes was hampered by adsorption on columns and insolubility in salt solutions. GPCs 
were finally obtained for C12-60 and C12-87 in water. Mn (polydispersity) for C12-60 was 8.2 
kDa (4.6) while the corresponding values for C12-87 were 20.5 kDa (1.9). Mn‟s for C12-60 and 
C12-87 from end group analysis were 18 and 21.9 kDa, respectively. The reason for the differing 
Mn‟s for C12-60 is not clear. Additional solution studies are required to provide comparative 
molecular weight data. 
Previously, a detailed analysis 
with related copolyoxetanes using 
simultaneous comonomer addition 
provided evidence for a random copolymer architecture.[58, 71] Given the similar reaction 
conditions and simultaneous comonomer addition, precursor BBOx-m copolyoxetanes are 
assumed to be a random copolymers having PEG and bromobutoxymethyl side chains.[56] 
However, compared to feed, the BBOx/ME2Ox mole ratios showed systematic enrichment for 
BBOx indicating BBOx monomer 3 is preferentially incorporated in the copolyoxetane under the 
reaction conditions employed.  
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Figure 1.1. MDSC curves for (A) C12-60 and (B) C12-87 
 
Corresponding C12-m copolyoxetanes 1 were obtained by overnight quaternization with 
dodecyldimethylamine. Table 1.3 shows the C12/ME2Ox mole ratios determined by 
1
H-NMR 
spectroscopy. Complete substitution for all C12-m was indicated by an intense peak between 1.2 
and 1.4 ppm for –N-(CH3)2CH2(CH2)10CH3 and the absence of a peak at 1.9 ppm for CH2 from 
BBOx-m. Analysis details are in Appendix A. Figure A2 shows the IR spectrum for BBOx-42 
and C12-43. The different compositional designations stem from round-off of 
1
H-NMR 
integrations.  BBOx-42 has a C-Br absorption peak at 650 cm
-1
, while no absorption is seen in 
the 515-690 cm
-1
 range for C12-43 as expected after quaternization.  
C12-m copolyoxetanes are slightly yellow, viscous liquids at ambient temperature. Modulated 
Differential Scanning Calorimetry (MDSC) showed Tg‟s ranging from -34 to -69 °C (Table 1.3). 
DSC thermograms are shown in Figure 1.1 for two representative C12-m copolyoxetanes (C12-
60 and C12-87) having Tg„s at -53 °C and -34 °C, respectively. Although the total number of 
atoms in the quaternary side chain is 19, there is no evidence of endotherms (0 – 125 °C) typical 
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of side chain crystallization.[72] The low Tg‟s may be compared with polycation “molten salts” 
(-64 to -72 °C)[73, 74] and attest to high molecular mobility. This is attributed to a combination 
of ME2Ox side chains and ether functionality in the main chain and in the linkage to the C12 
side chain. 
 
MIC Assay. Several growth media were explored in order to avoid C12-m copolyoxetane 
precipitation. Luria Broth (LB) solutions were prepared with a range of salt concentrations (0.1- 
3 wt%). Although adequate bacterial growth was observed, the copolyoxetanes precipitated in 
media with  0.5 NaCl wt%. Subsequently, a formulation was developed using M9 minimum 
growth medium that contained low salt and a small amount of glucose or mannitol (Table A1). In 
the M9 medium containing 1 vol% LB, a density of 10
8
 cells/mL was obtained overnight. E. coli 
and P. aeruginosa cultures grew well in the M9 mannitol media while S. aureus had less growth. 
A modified Tryptic Soy Broth (TSB), a comparatively richer medium, proved suitable for S. 
aureus growth (Table A2). The salt concentration in both media was similar (~ 5 g/L). Although 
two different media formulations were used for the MIC tests, the extent of growth for all three 
bacterial strains was comparable. This mitigates against a C12-m copolyoxetane salt effect for 
any particular strain. 
 
MIC values were determined by a standard macrodilution method.[31] The results are 
shown in Figure 1.1 and Table 1.4. Figure 1.2 shows that with increasing C12 mol% MICs 
decrease and reach a minimum at ~50 mol% C12. Further increases in C12 mol% have either a 
minimal effect (E. coli and P. aeruginosa) or a negative effect (S. aureus). 
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Figure 1.2. Log MIC (μg/ml) versus C12 mole percent for C12-m copolyoxetanes: (A) P. 
aeruginosa, (B) S. aureus, and (C) E. coli.  
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Table 1.4. MICs for three bacterial strains.  
 
C12  
(mole %)
 
 
MIC, µg/ml, (standard deviation) 
 
MIC per quaternary ammonium 
moiety (µM) 
 
E. coli P. aeruginosa S. aureus E. coli P. aeruginosa S. aureus 
14 300 (0) 410 (0) 250 (0) 5.3 6.4 3.9 
26 50 (5) 93 (11) 15 (5) 1.7 3.1 0.51 
43 5.7 (0.6) 33 (3) 5.3 (0.6) 0.68 3.9 0.64 
50 6.3 (0.6) 28 (2) 9 (1) 0.38 1.7 0.53 
60 5.3 (0.6) 26 (0.6) 10 (1) 0.17 0.87 0.33 
87 5.3 (0.6) 33 (5) 10 (1) 0.21 1.3 0.38 
100 5 (0) 28 (3) 13 (3)  0.44 2.5 1.1 
DTAB
a 
17 (6) 103 (15) 37 (6) 55 335 120 
 
a. DTAB = dodecyltrimethylammonium bromide 
 
P. aeruginosa is the bacterium most resistant to C12-m copolyoxetanes. The minimum 
MIC against P. aeruginosa is found for C12-60 (26 μg/ml). The resistance of P. aeruginosa has 
been demonstrated for most antimicrobials.[7] Additional lipopolysaccharides and other 
mechanisms are thought to decrease the interaction of antimicrobials with the membrane. Among 
all Gram(-) bacteria, P. aeruginosa has an overall outer cell membrane permeability that is 12-
100 times lower than E. coli.[9]  
 
The optimum C12-m composition range of 40-60 mol% is noteworthy and reflects the 
interaction of several molecular characteristics. Increasing C12 mole fraction not only increases 
charge but simultaneously changes amphiphilic balance by a combination of increased 
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amphiphilic quaternary ammonium mole fraction and decreased hydrophilic ME2Ox mole 
fraction. 
 
Comparative MIC performance. To facilitate comparison of antimicrobial performance for 
C12-m copolyoxetanes with related systems, Table 1.1 lists a selection of polycations in order of 
decreasing MICs in μg/ml, as commonly reported.[31, 32], [26, 33, 34, 36, 37, 39, 51, 52, 69, 75] 
MIC values in μM, that is MIC/Mn are also provided.[36, 37] For medical applications of 
antimicrobials, mass based units (MICs in μg/ml) are generally favored as the lower amount of 
material used the better.  
 
The representative polycation structures and MICs in Table 1.1 show biocidal 
performance varies widely from nil (> 2000 µg/ml) to levels rivaling commonly used antibiotics. 
For the latter, Tan reported MICs for penicillin of > 50 μg/ml against E. coli and < 0.1 μg/ml 
against S. aureus,[76] while MICs for ciprofloxacin are 0.42 μg/ml for S. aureus, 0.52 μg/ml for 
P. aeruginosa, and 0.013 μg/ml for E. coli.[77] As another reference point, a MIC of 125 μg/mL 
against  E. coli was reported by Palermo for the natural host defense peptide magainin-2.[36]  
 
 In Table 1.1 structures 4-7 are characterized by relatively high polarity and lack balanced 
amphiphilicity. Better performing compositions 10-15 have cationic segments accompanied by 
hydrophobic moieties that may be co-segments (9, 11, 15) or on opposite sides of the same 
repeat (10, 16). 
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Structure 13 has a diethylene glycol component in the main chain;[31] it is noteworthy 
that polycation 13 has high antimicrobial effectiveness similar to C12-m copolyoxetanes. 
Venkattaraman recently reported a series of polyacrylate copolymers 12 with diethylene glycol  
[CH3O(CH2CH2O)9-] and quaternary [R(CH3)2NCH2CH2O-] side chains.[51] The ratio of PEG 
to quaternary ammonium side chains was fixed at ~1:9 which is roughly comparable to C12-87. 
The MIC for 12 (B. subtilis, 20 µg/ml) was minimized for R = methyl, that is a 
trimethylammonium ethyl methacrylate repeat. Activity against Gram (+) B. subtilis was 
comparable to 8, 10, and 11 but considerably higher than 14 (4 µg/ml) and 16 (0.8 µg/ml). The 
study of 12 against B. subtilis showed that increasing the alkyl group length on the quaternary 
function resulted in considerably higher MIC. Thus, the presence of a PEG side chain in 12 does 
not necessarily confer high antimicrobial effectiveness, at least against B. subtilis.  
 
Structures with low MICs tend to have primary, secondary, or tertiary alkylammonium 
charge centers including 10, 11, 13, 15 and 16. In a series of butylacrylate copolymers, one with 
a charge fraction of 0.77 Me2HN
+
 side chains had a MIC of 3.8 μg/mL against E. coli, which was 
the lowest of all butylacrylates (including quat copolyacrylates).[36] MICs for C12-26 to C12-
100 against E. coli range from 50 (C12-26) to 5 (C12-100) μg/ml. This comparison demonstrates 
that the presence of an N-H moiety is not necessary to ensure low MICs. However, broad 
conclusions are precluded as factors such as testing methods and bacterial strains could influence 
results. 
  
A systematic antibacterial study was done on an amphiphilic pyridinium methacrylate 
series of copolymers represented by 8.[50] Mn for this series of copolymers was in a narrow 
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range (27 to 33 kDa) and the mole fraction quaternary charge was kept constant at 0.5. The 
minimum MIC (50 µg/ml) against E. coli was observed for a butyl copolymer. The C12-50 
copolyoxetane, which has a same linear charge density as 8 has a MIC of 6 µg/ml against E. coli.  
 
The butylacrylate series 9 is related to C12-m copolyoxetanes in that both linear charge 
density and amphiphilic character are changing simultaneously. Mn for the butylacrylate series 
ranged from 1.2 to 3.5 kDa while the C12-m copolyoxetanes have a broader molecular weight 
range (3.5 to 21.9 kDa, Table 1.3).  For butylacrylates 9, MICs against E. coli were similar for 
quaternary mole fractions from 0.56 to 0.63 (39-34 μg/mL). The MIC for butylacrylate 9 with a 
charge fraction of 0.63 (34 μg/mL) may be compared with that for C12-60 (5.3 μg/mL). 
Increasing quaternary mole fraction for 9 from 0.63 to 0.78 resulted in increasing MICs from 34-
1700 μg/mL.[36] In contrast, biocidal effectiveness for C12-m against E. coli is essentially 
constant (~ 5 μg/mL) for mole percents C12  50. Differences in testing procedures must be 
taken into account, but it is apparent that a combination of charge balance, amphiphilicity, and 
polyvalency for C12-50 – C12-87 compositions result in strong biocidal effectiveness against E. 
coli.  
 
Polycation effectiveness (PE). The ratio of monocation (dodecyltrimethyl ammonium bromide) 
to polycation MIC (μM) per alkylammonium provides a measure of polycation effectiveness 
(PE). Figure 1.3 shows PE versus quaternary mole percent for the three bacterial challenges 
(Table 1.5).  
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Figure 1.3. PE (polycation effectiveness) vs. mole fraction C12, where PE = ratio of MIC (μM) 
for DTAB to MIC (μM) for C12-m copolyoxetanes. 
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Table 1.5. PE (polycation effectiveness) vs. mole percent C12, where PE = ratio of MIC (μM) 
for DTAB to MIC (μM) for C12-m copolyoxetanes. 
 
C12 
(mol%) 
PE (MICDTAB/MICC12-m copolyoxetane) 
E. coli P. aeruginosa S. aureus 
14 12 52 31 
26 32 108 235 
43 81 86 187 
50 145 197 226 
60 324 385 364 
87 262 258 315 
100 125 134 109 
 
The PE for E. coli increases fairly regularly up to C12-60 and then decreases. Similarly, 
the PE for P. aeruginosa increases up to C12-60 and then decreases reaching a maximum of 385 
which stands out compared to all C12-m copolyoxetanes. The PE for S. aureus also has a 
maximum at C12-60 (364), but there is a different dependence of PE on composition compared 
to E. coli and P. aeruginosa. High PE values from C12-26 to C12-87 reflect the susceptibility of 
S. aureus to C12-m copolyoxetanes even at the low linear charge density C12-26 composition. 
Compared to DTAB, the combination of lowest quaternary charge fraction, lowest MIC, and 
highest PE against E. coli and P. aeruginosa is found for C12-60 which has 324 times higher 
activity against E. coli and 385 times more against P. aeruginosa (Table 1.5). 
 
MBC Assay. The determination of minimum bactericidal concentration (MBC) is crucial in the 
development of antibacterial agents. An MBC assay is important in determining concentration 
multiples (compared to MIC) that are required not just for inhibition of growth, but for bacterial 
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kill. The MBC assay is the same as the MIC assay, but an aliquot of the test medium is taken 
after the 24 hr exposure to the antimicrobial. There may be no bacterial growth from this aliquot 
if MIC and MBC are identical, or more commonly some multiple of MIC is required to affect 
kill (e.g., 99.99%). As points of reference, a previous study on Pexiganan, a magainin analog, 
showed that the MBC for some isolates of S. aureus was as high as 3 times the MIC,[78] while 
the MBC for antibiotics Linezolid and Daptomycin is 2 and 4 times MIC, respectively.[1] 
 
Table 1.6. Percent lysis for the three strains of bacteria at the respective MIC multiplier.
c 
 
MIC 
multiplier 
E. coli 
(% lysis) 
P. aeruginosa 
(% lysis) 
S. aureus 
(% lysis) 
0 Lawn Lawn Lawn 
1 had HD HD 
1.5 D
b
 99.99 D 
2 99.99 >99.99 99.99 
3 >99.999 >99.999 >99.999 
 
a. „HD‟ refers to a very high density of bacterial colonies. 
b. „D‟ refers to a high density of bacterial colonies. 
c.  Relative densities are Lawn > HD > D 
 
Copolyoxetane C12-43, one of the most effective compositions, was selected for 
assessment of MBC. Table 1.6 shows the log reduction in the bacterial colony count as a 
function of the MIC multiplier. From the MBC assay protocol, Table 1.6 shows that C12-43 
affects a 99.99% kill at 1.5 times MIC for S. aureus, while E. coli and P. aeruginosa require 2 
times MIC. In summary, susceptibility tests show MBC multipliers that are comparable to 
antimicrobials and antibiotics noted above.  
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Killing Kinetics. The determination of MIC is an initial step in evaluating antimicrobial 
behavior. MIC tests are typically done overnight and do not provide information on rate of kill. 
Kill kinetics are of importance in antimicrobial evaluation, but little information has been 
reported for polycations. Such “killing curves” are often the subject of studies for antibiotics.[79] 
Killing curves are often used to evaluate combinations of antibiotics and other moieties such to 
find synergistic relationships.[80, 81] As an initial evaluation of C12-m copolyoxetanes, C12-43 
was again selected for a study of the bacterial kill rate.  
 
For this investigation C12-43 concentrations were 5 and 10 times MIC.[78, 81, 82] The 
reduction in a bacterial challenge of ~ 10
8
 cfu/ml S. aureus, E. coli and P. aeruginosa was 
monitored for three consecutive hours. At 5× MIC, C12-43 concentrations were 30, 25, and 165 
μg/ml for S. aureus, E. coli and P. aeruginosa, respectively. These concentrations are higher than 
minimum biocidal concentrations. The results in Figure 1.4 show that at 5× MIC, C12-43 kills ≥ 
99% S. aureus, E. coli and P. aeruginosa within 1 hr. The log reductions after 1 hr were 2.3, 1.9, 
and 1.9 for S. aureus, E. coli and P. aeruginosa, respectively (Table 1.7). Additional kill was 
observed after 3 hours; log reductions increased to 2.8, 2.1 and 2.7 for the respective bacteria.  
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Figure 1.4. Log reduction of bacterial colony count for C12-43 vs. time. The log cfu/ml at t = 0 
is the initial concentration. Solid lines, 5× MIC (Table 1.4); dashed lines, 10 times MIC. 
 
 
At 10 times MIC, log reductions after 1 hr were 3.6, 2.9, and 4.8 for S. aureus, E. coli and 
P. aeruginosa, respectively; after 3 hr, log reductions increased to 4.9, 3.4, and 6.1 for the 
respective bacteria.  It is noteworthy that an order of magnitude greater kill for S. aureus and P. 
aeruginosa occurs during the additional 2 hr. More rapid kill kinetics are expected for such high 
concentrations, and parallel 10× MIC data for polycation CSA-13, 17.[38] 
 
While 10× MIC effects rapid kill, the C12-43 concentration is quite high. To place results 
in perspective (Table 1.7), kill kinetics for copolyoxetane C12-43 at 5× MIC are compared with 
two other polycations at similar concentrations. Kill kinetics for polycation 5 (Table 1.7) were 
evaluated against S. aureus.[26] Substantial differences in testing procedures are noted below. 
However, this is the only report we have found for kill kinetics for a polycation; the other 
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comparison is for a molecular polycation 17 with four charged sites. In view of the minimal 
information available for polycation kill kinetics, we also compare our observations with 
selected antibiotics. 
 
The MIC for 5 against S. aureus is at least 20 times higher (100-300 µg/ml) than that for 
C12-43 (5 µg/ml). In testing 5, a much lower concentration of S aureus (< 10
5
 cfu/ml) was used 
for the determination of MIC compared to that employed herein (~10
8
 cfu/ml). In any event, at 
5× MIC (25 µg/ml) C12-43 effects a 2.3 log reduction against S. aureus (ATCC-25904) after 1 
hr, while 5 effects a 3.6 log reduction. At the end of 2 hours the log reductions are 2.6 for C12-43 
and 5.5 for 5 (Table 1.7). 
 
Although the log reduction for polycation 5 is 10 to 1000 times higher than C12-43, the 
comparison is flawed as the starting inoculum for 5 (3.2 x 10
5
 cfu/ml is a factor of 10
3
 lower than 
that for C12-43 (1.9 x 10
8
 cfu/ml, Table 1.7). Savage noted an “inoculum effect” for polycation 
17 kill kinetics.1 When the challenge of a vancomycin-resistant strain of  S. aureus was ~5 x 10
8
, 
the cfu concentration after 3 hr (4× MIC) was >10
7
, while with an initial cfu concentration of  ~8 
x 10
5
 cfu the concentration after 3 hr was 10
3
.  Thus, the cfu decrement after 3 hr for the higher 
challenge was a factor of 10, but for the lower challenge was x 100. From these and other 
antimicrobial tests against vancomycin-resistant strain of S. aureus,
1
 we conclude that the lower 
challenge of S. aureus used by Ikeda against 5 accounts in large measure for the faster kill 
kinetics relative to C12-43. 
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 The MIC for molecular tetracation[1] 17 against a vancomycin-resistant strain of S. 
aureus is very low, 1 µg/ml.[1] Kill kinetics against S. aureus for 17 at 4× MIC (4 µg/ml) 
resulted in a 0.2 log reduction after 1 hr and a 1.6 log reduction after 4 hr (Table 1.7).[1, 38] By 
comparison, after 1 hr C12-43 at 5× MIC (25 µg/ml) effects a 2.3 log reduction against S. aureus 
(ATCC-25904) and 2.8 after 3 hr. Bacterial inoculate were similar for 17 (3.2 x 10
8
 cfu/ml) and 
C12-43 (1.9 x 10
8
 cfu/ml). A 2 log reduction corresponds to 99% kill. While the test conditions 
are similar, the mass per ml C12-43 (25 µg/ml) is six times higher than that for 17 (4 µg/ml).  
 
Table 1.7. Comparison of killing kinetic studies for S. aureus. 
 
Antimicrobial MIC, µg/ml 
(MIC multiplier) 
Challenge 
(cfu/ml) 
Log reduction 
1 hr 2 hr 3 hr 
  
C12-43 5 (5) 1.9 x 10
8
 2.3 2.6 2.8 
 
5 100-330 (0.3-0.1)  3.2 x 10
5
 3.1 5.5  
 
CSA-13, 17 1 (4) 3.2 x 10
8
 0.2 0.4 0.8 
 
 
Comparison of molecular and polymer amphiphilic polycations. The molecular, primary 
polyamines 16[39] and 17[38] share amphiphilic characteristics with C12-m copolyoxetanes. 
Both 16 and 17 have multiple hydrophilic amine/ammonium and hydrophobic olefinic 
components. The powerful biocidal activity of 16 and 17 is noteworthy. Unlike quaternary 
polycations, the amine/ammonium structure is pH dependent, but the ammonium form is stable 
at physiological pH.[36] Polycations 16[39]and 17[38] share a relatively rigid structure that 
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favors facile conjugation with negatively charged species on a membrane. It is apparent that 
unfavorable conformational changes are minimized while strongly favored, entropically driven 
(Eq. 2), multiple cation-anion interactions are maximized.  
Structure 16 is a dimer, which tends to minimize effects of polyvalency. However, 16 
requires minimal molecular reorganization in conjugating with the bacterial cell wall. In contrast, 
the chain structure of C12-m copolyoxetanes may require a more complex and entropically 
unfavorable reorganization for bacterial wall conjugation. 
Many structural variations have been carried out for polycation 17 to provide insight into 
the mechanism of antimicrobial action.[38] For example, the nature of the group extending from 
the central multi-ring core influences bactericidal activity of ceragenins against Gram(-) 
bacteria., such as E. coli.[48] A long alkyl chain confers effective biocidal action against Gram(-) 
E. coli at relatively low concentrations, whereas without this alkyl chain activity is essentially 
lost.[83] This finding is similar to the potent activity for the butyl ester copolymer 15 against E. 
coli but negligible effectiveness for the methyl ester analog.[36]  
Hemolytic activity.  The lytic activity of C12-m copolyoxetanes toward human red blood cells 
(RBC) was investigated as a measure of biocompatibility. Hemolysis was investigated at 
concentrations 2-10 times the MIC. Such concentrations are at or above the minimum biocidal 
concentration (MBC), the minimum concentration that kills all bacteria.  
Results from RBC hemolytic assays for C12-m copolyoxetanes, are summarized in Figure 1.5. 
For all C12-m copolyoxetanes, RBC lysis does not exceed 16% at 50 µg/ml. Interestingly, only 
modest dependence of percent lysis on concentration is observed. Below 50 µg/ml, RBC lysis 
does not exceed 10% for C12-26, C12-50 and C12-60. The order of hemolytic activity at ~ 40 
µg/ml is C12-26 ~ C12-50, ~ C12-60, > C12-87 ~ C12-100 > C12-43. C12-43 does not fall into 
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the regular trend of increasing cytotoxicity with increasing mole percent C12. At higher 
concentrations ( 40 µg/ml), C12-43 falls into the group (with C12-87 and C12-100 that have 
higher (13-15%) RBC cytotoxicity. At low concentrations (~ 10 µg/ml) all C12-m 
copolyoxetanes have very low hemolytic activity (< 8 %) except for C12-100 (11 %). C12-50 
and C12-60, which are highly efficient antimicrobials (Figure 1.2) are among the least cytotoxic 
C12-m copolyoxetanes. 
 
Figure 1.5. Percent RBC lysis as a function of C12-m copolyoxetane concentration. 
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One metric for defining hemolytic activity is HC50, the concentration of antimicrobial that kills 
50% of mammalian cells under investigation.[50, 69, 84] At C12-m copolyoxetane 
concentrations ≤ 50 µg/ml, RBC lysis is less than 16 % for all C12-m copolyoxetanes, 
precluding an HC50 determination. Inspection of the slopes for curves in Figure 1.5 shows that 
much higher concentrations are needed to affect 50% RBC lysis.  
Conclusion  
Ring opening copolymerization of 2 and 3 followed by quaternization of the BBOx-m 
intermediate gives C12-m copolyoxetanes 1 having PEG-like and C12 quaternary side chains 
with m = 14, 26, 43, 50, 60, 87, and 100 mole%. By analogy with prior work,[57-59] 
copolyoxetanes 1 are random copolymers (except for homopolymer C12-100). C12-m 
copolyoxetanes are polycation molten salts that are slightly yellow, viscous liquids with Tg‟s 
ranging from -34 to -69 °C (Table 1.3). 
1
H-NMR end group analysis gave relatively low 
molecular weights in the 4-20 kDa range. 
 
Although having long side chains (19 atoms), there is no DSC evidence (0 – 125 °C, 
Figure 1.1) for endotherms that are characteristic of side chain crystallization.[72] The low Tg‟s 
may be compared with polycation molten salts reported by Ohno (Tg = -64 to -72 °C)[73, 74] and 
attest to high mobility of the –CH2CH2CH2O- main chain. In addition, low Tg‟s are favored by a 
combination of ME2Ox side chains and ether functionality in the linkage to the C12 side chain. 
Polycations listed in Table 1.1 are typically reported as “solids” (no thermal transitions were 
found for 12).[33] It appears that C12-m copolyoxetanes are the first polycation molten salts 
examined as antimicrobials.  
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A systematic trend in composition versus antimicrobial activity was found for water 
soluble copolyoxetanes 1 with C12 alkylammonium side chains. This finding stands in contrast 
to recently reported polyvinyl amines where no direct relationship was found for antimicrobial 
activity and charge density.[85] As shown by other polycationics when compared to monovalent 
analogs,[29, 86, 87] C12-m copolyoxetanes had higher effectiveness against both Gram(+) and  
Gram(-) bacteria compared to monovalent DTAB. This polycation effectiveness (PE) can be 
understood in terms of the proposed entropic driving force described by Eq 2, whereby multiple 
equivalents of potassium salt are liberated by conjugation of a single polycation. Potassium ion 
release disrupts the bacterial cell potential contributing to cell death. A broad range of polycation 
activity, ranging from negligible to powerful reflects other important interactions such as 
amphiphilic balance and polycation architecture, the nature of which are not yet well understood. 
 
For C12-m copolyoxetanes, increasing quaternary alkylammonium content improves 
biocidal activity up to the compositional range C12-43 to C12-60 (Figure 1.2). A comparison 
with other antimicrobial polycations (Table 1.1) shows that C12-43 to C12-60 copolyoxetanes 
are among the most effective antimicrobials known against the tested Gram(+) and Gram(-) 
bacteria. For C12-m (m > 60), a static or gradual decrease in MIC is observed. A charge 
shielding or steric effect by the long alkyl chains due to increased occurrence of C12 diads, triads 
and higher sequences may be the reason for this gradual decrease in biocidal activity. 
Alternatively, the changes in antimicrobial effectiveness above m = 60 may be due to decreased 
hydrophilic character due to the increased prevalence of long alkyl chains. 
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Despite different compositions and different molecular weights for C12-43 (3.5 kDa), 
C12-50 (8.4 kDa), and C12-60 (18 kDa) copolyoxetanes, MICs against S. aureus are similar and 
low (5.3 – 10 µg/ml). This is a remarkable result considering the MIC sensitivity to compositions 
found in other polycations.[36, 51]  
 
Tew has noted that “Gram selectivity is rare” for amphiphilic polycations.[88]  Inspection 
of Figure 1.2 shows that copolyoxetanes with maximum biocidal activity (C12-43 to C12-60) 
indeed have similar antimicrobial effectiveness against Gram(+) S. aureus and Gram(-) E. coli. 
However, MICs for Gram(+) S. aureus and Gram(-) E. coli diverge as mole % C12 increases, 
reaching a maximum selectivity of 2.6 for Gram(-) E. coli at C12-100. Interestingly, this 
selectivity for E. coli compared to S. aureus is opposite that found for poly(oxanorbornene)s 
described by Tew.[88] For poly(oxanorbornene)s selectivity for S. aureus was driven by MICs 
against E. coli that were > 20 times those for the C12-m copolyoxetanes (m > 43). Comparisons 
must be qualified in light of different testing procedures and the different structures, notably the 
primary ammonium functionality for poly(oxanorbornenes) versus the quaternary C12-m 
copolyoxetanes. The selectivity of C12-m copolyoxetanes for Gram(-) E. coli may be compared 
with elegantly designed polypeptides that had very high Gram(-) selectivity.[89, 90] 
 
Few studies have been reported on polycation antimicrobials against P. aeruginosa. This 
Gram(-) bacteria has a low susceptibility toward antibiotics due to the presence of efficient efflux 
pumps.[11] Resistance to polycation antimicrobials may be due in part to low cell wall 
permeability.[9] Polycations studied by Ikeda showed that acrylates with pendant biguanide 
groups have MICs between 660-1000 µg/ml.[28] Poly(methyloxazoline) polycations have MICs 
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from 4000 to 45000 µg/ml.[91] Studies performed on Carbenicillin, an antibiotic belonging to 
the carboxypenicillin group, gave a strain-dependent MIC between 6-25 µg/ml.[92] The 
minimum MIC against P. aeruginosa was 26 µg/ml for C12-60 (Figure 1.2, Table 1.4). Also of 
note is the insensitivity of MIC (29.5, sd = 3.2) against P. aeruginosa for copolyoxetanes with  
43 mol% C12. This is noteworthy considering the range of molecular weights and linear 
quaternary charge density.  
 
For C12-43 at 5 times MIC a killing kinetics study showed ≥ 99% kill for S. aureus, E. 
coli and P. aeruginosa in the first hour. C12-43 has a minimum bactericidal concentration that is 
1.5 times MIC for S. aureus and 2 times MIC for E. coli and P. aeruginosa. This performance 
for C12-43 against S. aureus is comparable to some common antibiotics such as linezolid and 
Daptomycin.  
 
The biocompatibility of PEG-functionalized biomaterials is widely recognized[93-96] but 
few studies of PEGylated polycations have been carried out. Structure 13 has a diethylene glycol 
component in the main chain[31] and has high antimicrobial effectiveness similar to C12-m 
copolyoxetanes, but cytotoxicity against human cells is unknown. 
 
An optimized copolyacrylate 12 with [CH3O(CH2CH2O)9-] and (CH3)3N-CH2CH2-
OC(O)- side chains (~1:9 mole ratio) showed moderate antimicrobial effectiveness against B. 
subtilis (MIC 20 µg/ml) compared to 14 and 16.[51] The same copolyacrylate 12 had low 
cytotoxicity against mouse RBCs (< 10% at 100 μg/ml), but 12 with longer alkyl chains (C8, 
C12) caused 100% lysis at 50 μg/ml.[51] We did not test C12-m copolyoxetanes against 
 50 
 
Gram(+) B. subtilis, a common soil bacterium which is rarely found to be a human pathogen.[97] 
However, C12-87, which has a similar ratio of PEG-like:C12 side chains to 12 (with C12 side 
chains, 100% mouse RBC lysis), has relatively low human RBC cytotoxicity (~ 14% at 50 
μg/ml). While the tests conducted for 12 are quite different than those reported on C12-m, the 
conclusion reached by Yang that longer alkyl groups on quaternary side chains correlate with 
increased cytotoxicity[51] is certainly not general.  
 
C12-m copolyoxetanes 1 have antimicrobial effectiveness that is exceeded by few other 
polycations (Table 1.1). The molecular polycations 16 and 17 have important advantages of low 
MICs against well known pathogens and well defined chemical structures. The MIC for 16 
against E. coli is 0.8 µg/ml while the HC50, which is the concentration that kills 50% RBCs, is 14 
µg/ml. The MIC for C12-m against E. coli is ~ 5 µg/ml over the range C12-43 to C12-100, about 
6 times higher than 16. The HC50 for C12-m was not measured as low % RBC lysis (< 15%) was 
found up to 50 µg/ml for all compositions (Figure 1.5). For example, RBC lysis for C12-50 and 
C12-60, two of the optimum E. coli antimicrobials, was ~ 7% at 2× MIC (10 µg/ml). From the 
maximum % lysis observed for C12-50 and C12-60 (Figure 1.5) the selectivity for E. coli 
compared to RBCs must be much greater than 10.  
 
While C12-m copolyoxetanes have high antimicrobial effectiveness and low RBC 
cytotoxicity, the fundamental reasons behind these observations are not clear. As noted above for 
several polycations, what seem to be modest structural variations cause dramatic changes in 
antimicrobial effectiveness or cytotoxicity.  C12-m copolyoxetanes with m > 43 have similar 
overall antimicrobial effectiveness but subtle changes in selectivity for the pathogenic bacteria 
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employed. Although not general, the presence of the PEG-like ME2Ox side chain seems to play 
an important role in minimizing C12-m cytotoxicity. A recent study supportive of this contention 
has shown hemocompatibility of positively charged PAMAM dendrimers was greatly enhanced 
by PEGylation.[93]  
There are important issues that our initial study has raised concerning C12-m 
copolyoxetanes as antimicrobials. Among these are the need to control molecular weights, chain 
architecture, and composition to bring structure property relationships into better focus. 
However, the favorable performance of this easily prepared new class of biocompatible 
antimicrobials that are novel polymer ionic liquids is encouraging. Our results may lead to new 
options for applications such as wound care, lotions, and cosmetics that will combat continually 
emerging resistance to traditional antibiotics. 
 
Chapter 1 reprinted (adapted) with permission from Chakrabarty, S.; King, A.; Kurt, P.; Zhang, 
W.; Ohman, D. E.; Wood, L. F.; Lovelace,C.; Rao, R.; Wynne, K. J. Biomacromolecules 2011, 
12(3):757-69. Copyright (2011) American Chemical Society.  
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Chapter 2 
Cytocompatibility of Poly[(3,3-Quaternary/PEG)-Copolyoxetanes] 
 
ABSTRACT 
The determination of cytocompatibility for a novel class of copolyoxetanes with 
quaternary ammonium and PEG-like side chains is investigated. A precursor P[(BBOx-
m)(ME2Ox] copolyoxetane was prepared by cationic ring opening copolymerization of 3-((4-
bromobutoxy)methyl)-3-methyloxetane (BBOx) and 3-((2-(2-methoxyethoxy)ethoxy)methyl)-3-
methyloxetane (ME2Ox) to give random copolymers with 26-100 (m) mole% BBOx. Reaction 
of P[(BBOx-m)(ME2Ox)] with dodecyl dimethylamine gave the corresponding quaternary 
P[(C12-m)(ME2Ox)] polycation salts, designated C12-m.  A series of C12-m copolyoxetanes 
were obtained (m = 26 to 100). Cytotoxicity studies were performed with HFF (Human Foreskin 
Fibroblast) and HDF (Human Dermal Fibroblast) cell lines. From previously determined 
minimum inhibitory concentrations (MIC) for strains of E. coli, S. aureus and P. aeruginosa, 
HFF and HDF selectivity ratios (EC50/MIC) were determined. Previous studies have shown 
relatively low RBC values (HC50) and moderate to high selectivity ratios (HC50/MIC). The 
results of cytotoxicity studies show that the P[(C12-m)(ME2Ox)-MW] copolyoxetanes have 
relatively low cytotoxicity for HFF and HDF cell lines. The excellent antimicrobial behavior and 
human cell compatibility makes these novel copolyoxetanes potential candidates for therapeutic 
applications. 
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Introduction 
Cytotoxicity studies are an essential parameter in the evaluation of a compound as a 
potential therapeutic. Polymer disinfectants are frequently toxic to human cells or their 
cytotoxicities are not reported. [98] If researchers attempt to address the question of cytoxicity, 
studies usually focus exclusively on hemocompatibilties. Prior antimicrobial and 
hemocompatibility studies discussed in Chapter 1 showed the effectiveness of C12-m 
copolyoxetanes as antimicrobials and hemocompatibility with relatively low RBC values 
(HC50).[99]The present study attempts to further evaluate C12-m copolyoxetane therapeutic  
potential by examining their toxic effects on two types of human fibroblast cells: Human 
foreskin fibroblasts(HFFs) and human dermal fibroblasts (HDFs). 
 
Experimental 
 
Materials. Copolyoxetanes with PEG and quaternary pendant groups were synthesized and 
characterized as previously reported.[99] Copolyoxetanes were dissolved in Dulbecco's modiﬁed 
Eagle's medium (DMEM) in sterilized centrifuge tubes and vortexed to obtain homogenous stock 
solutions. Serial dilutions were prepared using DMEM. 
 
Immortalized human foreskin fibroblast cells and immortalized human dermal fibroblast 
cells were generously provided by Drs. Shawn Holt, Department of Pathology, and Dr. Valerie 
Kristoffer, Department of Radiation Oncology, both at Virginia Commonwealth University 
School of Medicine. 
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Cell Cytotoxicity Assays. Cytotoxicities are reported as EC50 values which indicate the 
concentration which brings about 50% lysis of the respective cell line. Cytotoxicity was tested 
using a CellTiter 96® Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI) and 
were run according to the manufacturer‟s protocol.[100] Human foreskin fibroblasts (HFFs) and 
human dermal fibroblasts (HDFs) were used to enhance relevance to medical applications and 
therapeutics. HFFs or HDFs were seeded in 96 well plates at a seeding density of 1.5 × 10
3
 
cells/cm
2
. After incubation at 37 ºC and 5% CO2 for 24 hr, the cells were exposed to sample 
solutions at different concentrations for 24 hr, followed by the addition of the tetrazolium dye 
solution to the wells and incubation for 4 hr. During this period, living cells convert tetrazolium 
into a formazan product. A stop solution was added to formazan and the plate absorbance was 
read at 570 nm using a Biomate3 Spectrophotometer (Thermo Electron Corporation). EC50 
values are determined by using concentration vs. absorbance plots.[101] From concentration vs. 
absorbance plots, a maximum absorbance (plateau) was obtained. EC50 values were determined 
by locating the concentration corresponding to one-half of the maximum. 
 
Results   
 In view of the effective antimicrobial performance for C12-m copolyoxetanes and low 
human red blood cells (RBCs) cytotoxicity reported previously [99] it was decided to further 
explore cytotoxity on human foreskin fibroblasts (HFFs) and human dermal fibroblasts (HDFs). 
No known studies for antimicrobial AMPs or their mimics have focused on HFF or HDFs. 
Cytotoxicity studies have been limited to RBC assays and were discussed in detail in Chapter 1. 
Below, cytotoxicity of C12-m copolyoxetanes are assessed in relation to changing mole percent 
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quaternary charge. Cytotoxicity assays with C12-m where m = 26, 43, 60, 87 and 100 were 
performed and the results are reported below.  
C12-m copolyoxetanes.  
Cytotoxicity for HFF and HDF cell lines. Cytotoxicity of C12-m copolyoxetanes was examined 
using the MTT assay. MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), is a 
yellow dye that is used as an indicator for cell viability. Mitochondrial enzymes present in living 
cells convert MTT dye into purple formazan which is solubilized. Absorbance of the resulting 
solution is determined at 570 nm. In a control with no polymer (i.e. cells and media only), the 
MTT dye is completely converted to formazan which is solubilized resulting in negligible MTT 
absorbance. With increasing concentration of C12-m copolyoxetanes, more cells are lysed so that 
less MTT is converted to formazan. This leads to increased MTT absorbance at higher C12-m 
concentrations. According to this protocol, the concentration of C12-m copolyoxetane at half the 
maximum absorbance corresponds to 50% cell lysis. A representative determination of EC50 for 
C12-43 for the HDF cell line is shown in Figure 2.1. 
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Figure 2.1. Absorbance at 570 nm of tetrazolium vs. C12-43 concentration; 4 hr exposure of 
human dermal fibroblast (HDF) cell line. The concentration at half maximum absorbance (EC50) 
is circled.  
 
EC50 cytotoxicity results for HFF and HDF cell lines are shown below in Table 2.1. It is 
evident that all C12-m copolyoxteanes are relatively nontoxic toward both human fibroblast cell 
lines with C12-25 and C12-43 being the least non-toxic. HDFs are relatively insensitive to mol% 
C12, but HFFs exhibit lower EC50 values for ≥ 60 mol%. Cytotoxicity is still considered minimal 
when compared to the bacterial MIC values. 
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Table 2.1. Cytotoxicities (HFF and HDF cell lines) and MIC values for three bacterial strains for 
C12-m copolyoxetanes, where m= mol% C12. 
 
 
 
Selectivities for C12-m copolyoxetanes. Based on previous MIC results for E. coli, S. aureus and 
P. aeruginosa [99] revisited in Table 2.1. Selectivity, S, defined by Eq.1, is a measure of the 
concentration required to lyse human cells compared to the minimal concentration for inhibiting 
the growth of bacteria (MIC). As a measure of cytotoxicity, it is important to recognize that 
selectivities provide an optimistic estimate of antibiotic effectiveness, as the MIC is typically 2-4 
times lower than the minimal biocidal concentration, MBC.[99]Nevertheless, the measurement 
of selectivity provides a guide for potential use of antimicrobials as antibiotics. High selectivities 
mean effective antimicrobial activity while minimizing effects on human cells. 
 
 
Copolyoxetane 
EC50 (µg/ml) Minimum Inhibitory Concentration (MIC, µg/ml) 
HFF  HDF E. coli S. aureus P. aeruginosa 
C12-26 43000 38000 50 (5) 15 (5) 93 (11) 
C12-43 44000 57000 5.7(0.6) 5.3 (0.6) 33 (3) 
C12-60 9000 55000 5.3 (0.6) 10 (1) 26 (0.6) 
C12-87 10000 33000 5.3 (0.6) 10 (1) 33 (5) 
C12-100 9000 23000 5 (0) 13 (3) 28 (3) 
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MIC
EC50S      Eq. 1   
   
Amphiphilic C12-m copolyoxetanes have low cytotoxicity and high selectivities. Table 
2.2 shows selectivities for HFF and HDF cell lines are highest for C12-43 and C12-60 
copolyoxetanes. For the HFF cell line, C12-43 have selectivities of 7820 (E. coli), 8310 (S. 
aureus) and 1340 (P. aeruginosa). For the HDF cell line, C12-60 has selectivities of 10400 (E. 
coli) and 2170 (P. aeruginosa) but lower selectivity for S. aureus (5540). Based upon prior   
C12-m copolyoxetane RBC assays[99], although it is difficult to make direct comparisons 
between different cell lines, it is apparent that HFFs and HDFs are more robust when compared 
to RBCs. This leads to much higher selectivity values for the former.   
 
Table 2.2. Selectivities for C12-m copolyoxetanes for HFFs, and HDFs. 
 
Copolyoxetane E. coli S. aureus P. aeruginosa 
HFF HDF HFF HDF HFF HDF 
C12-26 860 765 3110 2740 466 412 
C12-43 7820 10130 8310 10800 1340 1740 
C12-60 1700 10400 906 5540 355 2170 
C12-87 1890 6230 1010 3320 305 1010 
C12-100 1800 4600 750 1920 330 844 
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Conclusion. 
Previous work has shown that the C12-m copolyoxetanes are promising antimicrobials. 
The present investigation of cell compatibility has shown that certain compositions (particularly, 
C12-43 and C12-60) have low toxicity towards human fibroblast cells and have high selectivities 
(E. coli, S. aureus and P. aeruginosa). The water solubility of these polymers coupled with 
excellent antimicrobial behavior and cell compatibility makes these novel copolyoxetanes 
potential candidates for therapeutic applications. 
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Chapter 3 
PEG/quaternary copolyoxetanes: antimicrobial effectiveness, hemolytic and cytotoxic 
activity in response to alkyl side chain length 
 
ABSTRACT 
 
This study concerns the effect of changing quaternary alkyl chain length of quaternary 
ammonium/PEG copolyoxetanes on solution antimicrobial efficacy, hemolytic activity and 
cytotoxicity. Copolyoxetanes have an oxetane repeat unit with a quaternary side chain and a 
PEG-like hydrophilic repeat unit utilizing the monomers 3-((4-bromobutoxy)methyl)-3-
methyloxetane (BBOx) and  3-((2-(2-methoxyethoxy)ethoxy)methyl)-3-methyloxetane 
(ME2Ox). A precursor P[(BBOx)(ME2Ox)-50:50-5.7 ] copolyoxetane was generated via ring 
opening polymerization of BBOx and ME2Ox monomers with a BBOx  mole fraction of 0.50. 
The Mn of 5.7 kDa is obtained from 
1
H-NMR end group analysis. The desired quaternary 
ammonium segment results from a substitution of C-Br with a series of tertiary amines. The 
copolyoxetanes are represented as Cx-50, where 50 is the mole percent of quaternary repeat units 
and „x‟ is quaternary alkyl chain length (2, 6, 8, 10, 12, 14 or 16 carbons). The BBOx: ME2Ox 
ratio was confirmed by 
1
H-NMR spectroscopy. Modulated differential scanning calorimetry 
(MDSC) studies showed Tg‟s between -40 °C and -60 °C and melting endotherms for C14-50 
and C16-50. Minimum inhibitory concentration (MIC) tests were determined for E. coli, S. 
aureus and P. aeruginosa. A systematic dependence of alkyl chain length and MIC was found. 
The most lethal antimicrobial was C8-50 with MIC values of (MIC in μg/ml, bacteria) 4 μg/ml, 
E. coli, 2 μg/ml, S. aureus and 24 μg/ml, P. aeruginosa.)  Kill kinetics for C8-50 were obtained 
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at 5 times MIC. This concentration effected >99% kill in 1 hour for a challenge of 10
8
 cfu/ml  
with log reductions of 7, 3, and 5 for S. aureus, E. coli and P. aeruginosa, respectively, at the 
end of 1 hour. 
Cx-50 copolyoxetane cytotoxicity toward human red blood cells, human dermal fibroblasts 
(HDF), and human foreskin fibroblasts (HFF) was low indicating good prospects for 
biocompatibility. This novel class of copolyoxetanes with tunable compositions offers 
opportunities for applications as therapeutic agents.  
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Introduction  
 
 Over the past two decades, several naturally occurring peptides have been isolated and 
found to possess antimicrobial properties. These naturally occurring antimicrobial peptides 
(AMPs) have an amphiphilic architecture, are water soluble and inhibit the growth of bacteria at 
low concentrations.[19, 20] These AMPs provide the first line of defense against bacterial 
infections and participate in innate immune response.[21, 102] In humans, AMPs are found 
primarily in tissues that are exposed to the most bacteria (skin, mucous membranes, and 
gastrointestinal tract). The widespread occurrence of AMPs in a diverse range of organisms 
further suggest these innate components of immunity defense control bacterial growth.[103]  
Although promising as therapeutics, AMPs are difficult and cost prohibitive to isolate and many 
have insufficient biostability.[104] Inspired by the amphiphilic nature of these naturally 
occurring antimicrobial peptides, synthetic analogs have been prepared that mimic AMP 
structure and properties.[105]  These AMP analogs can have increased potency by one to two 
orders of magnitude for inhibiting the growth of microbes.[106] 
 
 In connection with exploring 
amphiphilic soft blocks for contact-kill 
coatings, a novel class of copolyoxetanes 1 
was developed.[22, 56] These 
copolyoxetane soft blocks were used to 
create copolyoxetane soft block  
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polyurethane surface modifiers.[56, 107] An interesting feature of copolyoxetanes 1 (when x = 
12) regardless of mole %, is they are viscous, molten salts with low glass transition temperatures.  
 With charged and uncharged segments, 1 has AMP-like characteristics. Copolyoxetanes 1 
have quaternary alkyl  side chains and PEG-like ME2Ox side chains.   
Water solubility for P[(C12-m)(ME2Ox)] copolyoxetanes led to an investigation of 
solution biocidal properties. C12-m copolyoxetanes with m = 14, 25, 42, 50, 60, 87 and 100 were 
tested against E. coli, P. aeruginosa and S. aureus.[99]  Standard minimum inhibitory 
concentration (MIC) assays[31, 34, 36] showed that C12-m copolyoxetanes with m = 40-60 had 
maximum biocidal efficiency. C12-43 had the lowest MIC for E. coli (5.7 µg/ml) and S. aureus 
(5.3 µg/ml) while C12-60 had the lowest MIC for P. aeruginosa (26 µg/ml). Killing kinetic 
assays with the C12-43 at a concentration of 5 times MIC gave >99% kill in 1 hr for all the three 
bacterial strains with a starting inoculum ~ 10
8
 cfu/ml.  
 By analogy with AMPs, the killing mechanism for polycations is explained by ionic and 
hydrophobic interactions between the bacterial cellular membrane and multiple ammonium 
moieties.[108] Disruption of the phospholipid bilayer includes ion diffusion through cell wall ion 
channels and a change in cell potential that results in cell death.[55]  
Previous research on biocidal polycations shows biocidal performance varies widely from 
nil (> 2 mg/ml) to levels rivaling commonly used antibiotics. For the latter, Tan reported MICs 
for penicillin of > 50 μg/ml against E. coli and < 0.1 μg/ml against S. aureus,[76]while MICs for 
ciprofloxacin are 0.42 μg/ml for S. aureus, 0.52 μg/ml for P. aeruginosa, and 0.013 μg/ml for E. 
coli.[77] As another reference point, a MIC of 125 μg/mL against  E. coli was reported by 
Palermo for the natural host defense peptide magainin-2.[36]  
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A previous analysis of antimicrobial polycations showed poor performance for structures 
with high polarity and a lack of balanced amphiphilicity.[99]  Better performing compositions 
were found to have cationic segments accompanied by hydrophobic moieties that may be co-
segments or on opposite sides of the same repeat.  
Amphiphilic balance effecting 
biocidal activity can be very sensitive 
to what appears as a modest 
structural change.  For example, it is 
remarkable that changing butyl 
acrylate in structure 2 to a methyl  
acrylate results in a 100 times 
increase in MIC for E. coli.[36]   
Another example is found for 
“CSA-13”, 3, a molecular 
polycation.[38]An  octyl substituent 
(shown) results in a low MIC against Gram(-) E. coli, whereas without this group, activity is 
lost.[48]  
In view of the sensitivity of biocidal potency to amphiphilic balance, we have 
investigated the effect of changing alkyl chain length on the antimicrobial properties of  
copolyoxetanes 1. Based on prior work that showed the highest antimicrobial potency for C12-m 
with m = 40-60,[99] a series of Cx-50 copolyoxetanes were prepared (1, x = 2, 6, 8, 10, 12, 14 or 
16 carbons). Minimum inhibitory concentration (MIC) assays were carried out to assess relative 
antimicrobial effectiveness.  Kill kinetics were established for C8-50, which is the most 
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antimicrobial Cx-50 copolyoxetane. At 5 times MIC, for a starting inoculum of 10
8
 cfu/ml, C8-
50 affected a kill >99% in 1 hour. Details of this investigation are reported below. 
 
Experimental 
 
Materials. 3-bromomethyl-3-methyloxetane (BrOx) was generously provided by OMNOVA 
Solutions (Akron, OH). N,N-dimethylethylamine (C2), N,N-dimethylhexylamine (C6), N,N-
dimethyloctylamine (C8), N,N-dimethyldecylamine (C10), N,N-dimethyltetradecylamine (C14), 
and N,N-dimethylhexadecylamine (C16) were obtained from Aldrich. N,N-
dimethyldodecylamine (C12) was a gift from Lonza (Allendale, NJ). Methylene chloride 
(CH2Cl2), and tetrahydrofuran (THF) were obtained from Aldrich and dried by storing over 4Å 
molecular sieves. Boron trifluoride dietherate (BF3O(C2H5)2), tetrabutylammonium bromide 
(TBAB), 3-(hydroxymethyl)-3-methyloxetane, 1,4-dibromobutane and sodium hydride (NaH) 
were also obtained from Aldrich and used as received. 1,4-Butanediol (BD) and 2-(2-
methoxyethoxy)ethanol were purchased from Acros Chemicals and used as received. All M9 
media components were purchased from Sigma Aldrich. Luria Broth (LB) was purchased from 
Fisher Scientific. 
Human red blood cells (RBCs) were obtained from Innovative Research (Novi, MI) 
packed and transported on ice in a cooler (~ 4 °C), refrigerated upon receipt and used within one 
week. Immortalized human foreskin fibroblast (HFF) cells and immortalized human dermal 
fibroblast (HDF) cells were generously provided by Drs. Shawn Holt, Department of Pathology, 
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and Dr. Valerie Kristoffer, Department of Radiation Oncology, both at Virginia Commonwealth 
University School of Medicine. 
 
Synthesis and Characterization. The monomers 3-((4-bromobutoxy)methyl)-3-methyloxetane 
(BBOx) and 3-((2-(2-methoxyethoxy)ethoxy)methyl)-3-methyloxetane (ME2Ox) were 
synthesized and purified as described previously.[99] Copolyoxetane precursor 
P[(BBOx)(ME2Ox)] was analyzed by 
1
H-NMR to determine the co-repeat mole ratio. End group 
analysis was employed using trifluoroacetic anhydride (TFAA) for determining the number 
average molecular weight (Mn).[57] 
 
P[(BBOx)(ME2Ox)] copolyoxetane precursor synthesis. The target copolyoxetane intermediate 
was synthesized by cationic ring opening polymerization in CH2Cl2 by a procedure previously 
described.[99] ME2Ox (10g, 49 mmol), BBOx (9.5g, 40.9 mmol), 1,4-butanediol ( 0.538g, 6 
mmol) and BF3.OEt2 (1496 µl, 12 mmol) were used for P[(BBOx)(ME2Ox)-50:50] preparation. 
A higher ME2Ox feed molar ratio was used (55 mol%) as BBOx is somewhat more reactive.  
 
 P[(BBOx)(ME2Ox)-50:50-5.7 ] characterization: 
1
H-NMR (CDCl3):  0.91 ppm (-CH3, 
3H,s), 1.68 ppm (Side chain –OCH2CH2CH2CH2Br, –CH2-for BBOx,  2H), 1.92 ppm 
(-OCH2CH2CH2CH2Br, –CH2-for BBOx,  2H),   3.19 ppm (main chain –CH2-, 4H,m), δ3.30 
ppm (-CH2, 2H, s), 3.38 ppm (-OCH3 3H, s), 3.4 ppm (-CH2Br-, 2H), 3.55 ppm (-OCH2CH2O-, 
4H, m), 3.64 ppm (-OCH2CH2O-, 4H, m). Molecular weight (Mn) by 
1
H-NMR end group 
analysis was 5.7 kDa. The mole percent of the bromobutoxy group was calculated using 
equations described in Appendix A. 
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Cx-50 copolyoxetane synthesis.  Safety Note: Dimethylalkylamines are toxic; C2, C4, and C6 
are hazardous due to volatility. Reactions were carried out in a well ventilated hood using 
appropriate personal safety equipment. C2-50 was made with caution using small quantities of 
dimethylethylamine. Dimethybutylamine, the amine precursor for C4-50 was not commercially 
available. 
 
P[(BBOx)(ME2Ox)-50:50-5.7 ] was quaternized with tertiary amines to obtain Cx-50 
copolyoxetanes by a method described previously for C12-m copolyoxetanes.[99] The 
copolyoxetanes are represented as Cx-50, where 50 is the mole percent of quaternary repeat units 
and „x‟ is quaternary alkyl chain length (2, 6, 8, 10, 12, 14 or 16 carbons).The quantities of the 
P[[(BBOx)(ME2Ox)] precursor and the respective tertiary amines used for quaternization is 
provided in Table 3.1. After removing solvent and excess amine in vacuo (liquid nitrogen trap), 
Cx-50 copolyoxetanes were isolated as highly viscous liquids. 
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Table 3.1. Reactants for quaternization of P[(BBOx)(ME2Ox)-50:50-5.7] copolyoxetanes 
 
 
    
 
 
 
 
 
 
a. Ratio of Cx to ME2Ox repeats obtained from 
1
H-NMR integration. 
 
Characterization: Figure 3.1 shows the 
1
H-NMR spectrum for P[(BBOx-50)(ME2Ox)-50:50] 
and the C8-50 copolyoxetane. The 
1
H-NMR chemical shifts for C8-50 are: 
1
H-NMR (CDCl3):  
0.91 ppm (-CH3, 6H,s), 1.2~1.4 (-CH2(CH2)6CH3, 12H), 1.68~ 1.92  ppm(-OCH2CH2CH2CH2N-,  
4H, broad),  3.19 ppm (main chain –CH2-, 6H,m), 3.30 ppm (-CH2, 2H, s), 3.38 ppm (-OCH3 
3H, s), 3.4 ppm (-CH2N- 2H, CH3-N-CH3,6H), 3.55 ppm (-OCH2CH2O-, 4H, m), 3.64 ppm 
(-OCH2CH2O-, 4H, m). 
  
Instrumentation: 
1
H-NMR characterization was done using a Varian Mercury 300 MHz NMR 
spectrometer, FTIR spectra were obtained with a Magna-IR 760 spectrometer, Modulated 
Differential Scanning Calorimetry (MDSC) utilized a DSC Q1000 (TA Instruments).  
 
 x P[(BBOx-50)(ME2Ox)] g 
(mmol) 
 
Cx amine g (mmol)  Cx/ME2Ox
a
 
 6 2.5 (0.439) 1.42 (11.0) 
 
49.5/50.5 
 8 2.18 (0.382) 1.55 (9.87) 
 
50/50 
10 2.5 (0.439) 1.75 (9.46) 
 
50/50 
12 3 (0.526) 4 (13.6) 
 
50/50 
14 2 (.0351) 2.17 (10.14) 
 
50/50 
16 1.51 (0.265) 1.84 (6.84) 
 
50/50 
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Antimicrobial Testing. Bacterial suspension preparations, media for minimum inhibitory 
concentration (MIC) tests, MIC tests, and the procedure for kill kinetics assays were identical to 
those described previously.[99] and are discussed below. 
 
Antimicrobial activity assay. 
Bacterial strains. Three strains, which represent potential pathogens, were used to enhance 
relevance to medical applications and therapeutics. For the biocidal tests, strains used were 
Escherichia coli DH5α, Pseudomonas aeruginosa PA01 and Staphylococcus aureus ATCC-
25904. The cultures were streaked on Luria Agar plates and incubated overnight at 37 ºC. A 
single colony from each strain was used to inoculate 6 ml of Luria Broth (LB), grown overnight 
at 37 ºC with vigorous shaking (225 rpm). A sample was diluted in fresh medium and incubated 
to 10
8
 – 109 colony forming units per milliliter (cfu/ml) of the desired bacteria to generate a 
culture in the logarithmic growth phase.  
 
Media. Luria Broth (LB) was the standard medium for MIC evaluations. However, the Cx-50 
copolyoxetanes precipitated in LB. Different media formulations were tested that would prevent 
polycation precipitation and at the same time generate ample bacterial growth during the 24-hr 
incubation period. M9 growth medium was prepared containing 20 wt% mannitol as a carbon 
source for E. coli and P. aeruginosa and is referred to as “M9 mannitol” medium. However, 
significant growth for S. aureus was not observed. A modified Tryptic Soy Broth (TSB) was 
chosen for MIC evaluation of S. aureus as good growth was observed. 
  Several growth media were explored in order to avoid Cx-50 copolyoxetane precipitation. 
Luria Broth (LB) solutions were prepared with a range of salt concentrations (0.1- 3 wt%). 
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Although adequate bacterial growth was observed, the copolyoxetanes precipitated in media with 
 0.5 NaCl wt%. Subsequently, a formulation was developed M9 mannitol medium that 
contained low salt and a small amount of mannitol. In the M9 mannitol medium containing 1 
vol% LB, a density of 10
8
 cfu/ml was obtained overnight. E. coli and P. aeruginosa cultures 
grew well in the M9 mannitol media while S. aureus had less growth. A modified Tryptic Soy 
Broth (TSB), a comparatively richer medium, proved suitable for S. aureus growth. The salt 
concentration in both media was similar (~ 5 g/L). Although two different media formulations 
were used for the MIC tests, the extent of growth for all three bacterial strains was comparable. 
This mitigates a Cx-50 copolyoxetane salt effect for any particular strain.  
 
MIC Assays. MIC values for Cx-50 copolyoxetanes were determined by standard methods. [34, 
36, 69] Stock solutions were made by dissolving different concentrations of Cx-50 
copolyoxetanes in distilled water. The media (6 ml of M9 mannitol for E. coli and P. aeruginosa 
or TSB for S. aureus) were placed into Erlenmeyer flasks. Serial 1:2 dilutions of Cx-50 
copolyoxetane stock solutions and 60 µl of the bacterial cultures (~ 10
8
 cfu/ml) were added 
sequentially to the flasks to establish an initial range for MIC values. In order to determine MIC 
values with more precision, series were re-run within the initial range at smaller concentration 
differences (1µg/ml). The flasks were then kept in shakers at 37 ºC for 24 hours. Each series of 
tests were performed in triplicate. Bacterial growth was examined by measuring solution optical 
density at λ = 600 nm (OD600) as well as examination of turbidity visually. This MIC assay, 
which depends on a change in optical density of two orders of magnitude and a visual 
observation of solution transparency, provides confirmation of complete inhibition, that is, 
MIC.[34, 36, 70] 
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Kinetics of C8-50 copolyoxetane on bacterial killing. Agar plates were streaked with either E. 
coli, P. aeruginosa, or S. aureus from a frozen stock culture at -70 
o
C and incubated at 37 
o
C for 
18-24 hrs. From this plate, a single colony was collected and used to inoculate 6 ml of Luria 
broth. This culture solution was incubated for 18-24 hrs at 37 
o
C. A subculture was made by 
preparing a 1:100 dilution in LB and incubated at 37 ºC until it reached an optical density of ~ 
0.5 by UV-VIS (logarithmic growth phase).  A 20 ml aliquot of this bacterial culture was spun 
down to a pellet for 10 min at 10,000 rpm in a centrifuge. The supernatant was discarded and the 
pellet was dissolved in 20 ml of the respective growth media used for the MIC tests (M9 
mannitol for E. coli, P. aeruginosa, or TSB for S. aureus). The bacterial culture was divided into 
two equal volumes; one served as the control, while C8-50 copolyoxetane was added to the other 
at the desired concentration. C8-50 was chosen for the kinetic kill study as it had the lowest MIC 
values. At selected times (t = 0, 1 hr, 2 hr, 3 hr) 1 ml aliquots were taken from both the control 
and sample flasks and spun into a pellet in a microcentrifuge for 3 minutes at 1400 rpm. The 
supernatant was discarded and the pellet was resuspended in saline solution. The same cycle was 
repeated twice until the pellet suspended in saline contained no growth media. A serial dilution 
series was performed with 100 µL of the bacterial culture in saline. 100 µL aliquots were taken 
from each dilution and plated on Luria agar plates. These plates were incubated at 37 ºC for 24 
hours. The number of colonies were counted and compared with the control to obtain percent kill 
as a function of time.  
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Cytotoxicity Testing. 
 
Hemolytic activity assay. One metric for defining hemolytic activity is HC50, the concentration 
of antimicrobial that kills 50 % of RBCs under investigation.[50, 69, 84]A red blood cell lysis 
assay was developed following the procedure described by Palermo and Kuroda.[36] Red blood 
cells, RBCs (1ml), were diluted with 9 ml of phosphate buffered saline, PBS, (i.e. 10mM 
phosphate, 138 mM NaCl, pH 7.4, Sigma) and then centrifuged at 1000 rpm for 5 min. The 
resulting supernatant was removed using a pipette making sure not to disturb the RBCs and these 
steps repeated two more times. The assay stock (90 µL) was mixed with each of the polymer 
solutions (10 µL) on a sterile 96 well round bottom polystyrene microplate to give a final 
solution of 3.3% v/v RBC. Based on a hemacytometer count, this was approximately 10
8 
red 
blood cells per ml. 
 
 PBS (10 µL) or Triton X-100 (10 µL, 1% v/v) was added to the assay stock solution as 
respective negative and positive hemolysis controls. Triton X-100, a non-ionic surfactant is 
commonly used as a positive control in hemolysis assays.[36] For tests employing C12-m 
copolyoxetanes, 10 µL of stock solutions were added. The 96-well microtiter plate was secured 
in an orbital shaker at 37 °C and 250 rpm for 1 hr and then centrifuged at 1000 rpm for 10 min. 
The resulting supernatant (10 µL) from each well was transferred to a new sterile 96-well round 
bottom polystyrene microplate and diluted with PBS (90 µL). 
 
 Absorbance at 405 nm, characteristic of cell lysis,[36] was determined using a Versamax 
EXT microplate reader (Molecular Devices, Sunnyvale, CA) Negligible absorbance was 
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observed for the negative control (PBS) while the absorbance for the positive control was 3.9. 
The fraction of hemolysis is defined as the absorbance for copolyoxetane treated wells divided 
by the average of readings from the positive control wells. Hemolysis was plotted as a function 
of Cx-50 concentration to obtain HC50, the copolyoxetane concentration that causes 50% 
hemolysis relative to the positive (Triton-X) control.  Two separate trials were carried out in 
triplicate for each assay trial. Values reported are the average of the two trials.  
 
Human cell cytotoxity assay. Cytotoxicities are reported as EC50 values which indicate the 
concentration which brings about 50% lysis of the respective cell line. Cytotoxicity was tested 
using a CellTiter 96® Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI) and 
were run according to the manufacturer‟s protocol.[100] Human foreskin fibroblasts (HFFs) and 
human dermal fibroblasts (HDFs) were used to enhance relevance to medical applications and 
therapeutics. HFFs and HDFs were seeded in 96 well plates at a seeding density of 1.5 × 10
3
 
cells/cm
2
. After incubation at 37 ºC and 5% CO2 for 24 hours, the cells were exposed to sample 
solutions at different concentrations for 24 hours, followed by the addition of the tetrazolium dye 
solution to the wells and incubation for 4 hours. During this period, living cells convert 
tetrazolium into a formazan product. A stop solution was added to formazan and the plate 
absorbance was read at 570 nm using a Biomate3 Spectrophotometer (Thermo Electron 
Corporation). EC50 values are determined by using concentration vs. absorbance plots.[101] 
From concentration vs. absorbance plots, a maximum absorbance (plateau) was obtained. EC50 
values were determined by locating the concentration corresponding to one-half of the 
maximum. 
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Results  
 
 Biocidal efficacy of water soluble C12-m copolyoxetanes was previously demonstrated, 
wherein the quaternary alkyl chain length was 12 carbon atoms (1, x = 12, m = C12 mole 
fraction). The optimum antibacterial activity was observed for copolyoxetanes containing 40-60 
mole % C12.[99] To explore further amphiphilic balance, the present study investigates the 
effect of alkyl chain length for Cx-50 copolyoxetanes, where x = 2, 6, 8, 10, 12, 14 and 16. These 
copolyoxetanes were prepared via the intermediate P[(BBOx)(ME2Ox)-50:50-5.7 ]. The mole 
percent alkylammonium was constant and was in the middle of the range found most effective 
for C12. Preparation and characterization are briefly described followed by results from solution 
biocidal studies.  
 
Cx-50 copolyoxetanes. Cx-50 copolyoxetanes 1 were prepared in two steps. First the 
intermediate P[(BBOx)(ME2Ox)-50:50-5.7 ] was prepared. 
1
H-NMR confirmed mole ratios 
while end group analysis with TFAA (trifluoroacetic anhydride) provided a molecular weight 
(Mn) of 5.7 kDa. The second step was quaternization of the copolyoxetane precursor with the 
respective tertiary amines. The substitution reaction was carried out at 60 ºC except for the 
reaction with C2 amine. For C2, the reaction was carried out at 10 ºC and utilized an ice jacketed 
condenser. 
Complete substitution of the C-Br in the P[(BBOx)(ME2Ox)-50:50-5.7 ] precursor to the 
respective Cx-50 copolyoxetanes was obtained as shown via 
1
H-NMR spectroscopy (Table 3.1). 
Representative 
1
H-NMR spectra for the P[(BBOx-50)(ME2Ox)] precursor and C8-50 are shown 
in Figure 3.1 A and B, respectively. In the spectrum of C8-50 the absence of precursor peaks at 
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1.9 ppm (–CH2CH2CH2CH2Br) is noteworthy. New peaks at 1.2-1.3 ppm (-CH2(CH2)6CH3 from 
C8) are characteristic for the C8 substitution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cx-50 copolyoxetanes are viscous liquids at ambient temperature with Tg‟s ranging from 
-40 to -60 °C (Figure 3.2). Cx-50 copolyoxetanes have Tg‟s that are 10-20 °C higher than 
P[(BBOx)(ME2Ox)-50:50-5.7 ] due to presence of strong polar interactions from quaternary salt 
functionality. The low Cx-50 Tg‟s compare favorably with polycation salts that are molten salt 
 
Figure 3.1. 
1
H-NMR of (A) - P[((BBOx)ME2Ox) -50:50] and (B) - C8-50 
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analogs (-64 °C to -72 °C).[73, 74] The low Tg‟s for Cx-50 copolyoxetanes attest to high 
molecular mobility. This is attributed to a combination of ME2Ox side chains and ether 
functionality in the main chain and in the linkage to the alkyl side chain. 
  
 
Figure 3.2. MDSC thermograms for the Cx-50 polyoxetanes: (A) C2-50 (B) 
C6-50 (C) C8-50 (D) C10-50 (E) C12-50 (F) C14-50 (G) C16-50 and       
(H) P[(BBOx)(ME2Ox)-50:50-5.7].  
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The MDSC thermograms for the C14 and the C16 show endotherms at -7 °C and at        
10 °C, respectively (Figure 3.2). These endotherms are attributed to melting of phases formed by 
C14 and C16 side chains. Compared to poly(n-alkyl)acrylate)s, for which side chains with 8 
atoms crystallize,[110] the onset of crystallization is x = 14 for the Cx-50 copolyoxetanes. The 
low Tm‟s and higher chain length for crystallization for the Cx-50 copolyoxetanes are due to the 
lower linear density of hydrocarbon side chains.  
 
MIC Assays. Three common pathogenic bacteria were the subject of minimum inhibitory 
concentration (MIC) tests: Gram(-) E. coli and P. aeruginosa and Gram (+)  S. aureus. The effect 
on MIC for changing the Cx-50 quaternary alkyl side chains is shown in Figure 3.3. The most 
potent antimicrobials are C6-50, C8-50, and C10-50. C8-50 is at the center of a shallow 
minimum in the bar-graphed data. MICs for C8-50 are 4 μg/ml (E. coli), 2 μg/ml (S. aureus) and 
24 μg/ml (P. aeruginosa). Overall, C8-50 is the most effective antimicrobial against the three 
bacterial strains tested.  
 
Relatively high MIC values are observed for P. aeruginosa, which is the most resistant 
bacterium to all Cx-50 copolyoxetanes. C8-50 (24 μg/ml) and C10-50 (25 μg/ml) have similar 
MICs against P. aeruginosa,   Previously, a minimum MIC (26 μg/L) against P. aeruginosa was 
found for C12-60.[99] The resistance of P. aeruginosa has been demonstrated for most 
antimicrobials.[7] Additional lipopolysaccharides and other mechanisms are thought to decrease 
the interaction of antimicrobials with the membrane. Among all Gram(-) bacteria, P. aeruginosa 
has an overall outer cell membrane permeability that is 12-100 times lower than E. coli.[8-10]  
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The least effective Cx-50 copolyoxetane is C2-50 with MICs >90 µg/ml for Gram(-)      
E. coli and Gram(+)  S. aureus and > 120 µg/ml for P. aeruginosa (Figure 3.3). Depending on 
the bacterial strain, an increase in MIC of 4-45 times is observed for C2-50 compared to C8-50. 
For C2-50 the amphiphilic balance is clearly shifted in a way that precludes effective conjugation 
with bacterial membranes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This attenuation of biocidal efficiency resulting from shortening the alkyl chain can be compared 
with two related cases cited above. Palermo noted that changing the butyl group in structure 2 to 
a methyl group resulted in a 100 times increase in MIC for E. coli,[36] while Savage found that a 
 
 
 
Figure 3.3. Minimum Inhibitory Concentrations as a function of quaternary chain length for 
Cx-50 copolyoxetanes. - E. coli, - S. aureus, and  - P. aeruginosa. 
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long alkyl chain for the molecular polycation “CSA-13”, 3 was essential with a low MIC against 
E. coli. [48]  
 
The results shown in Figure 3.3 may be compared with those for a series of amphiphilic 
polyoxanorbornenes 4 with varying quaternary alkyl side 
chains.[52]. With R = ethyl or butyl the MIC was 200 
µg/ml for E. coli, while for hexyl and octyl analogs the 
MIC decreased to12.5  and 4 µg/ml, respectively. For R =  
decyl, the MIC increased to 12.5 µg/ml. A similar trend 
was observed for Gram (+) B. subtilis. Considering the 
different molecular structures of 1 and 4, the trends are 
remarkably similar.  
 
A MIC minimum was also observed for amphiphilic 
pyridinium methacrylate copolymers by Sen.[50] The 
highest antimicrobial efficiency against E. coli was 
observed for the butyl copolymer 5 (50 µg/ml), but the MIC 
was 550 µg/ml for the ethyl analog.  Above butyl, MICs 
increased with increasing alkyl chain length, reaching 1000 µg/ml for the decyl analog. 
However, against Gram (+) B. subtilis a drop in MIC occurs from ethyl (300 µg/ml) to hexyl (30 
µg/ml). Increasing the chain length to decyl increased the MIC to 300 µg/ml. Thus, compared 
with the optimum C8-50 copolyoxetane 1 and polyoxanorbornenes 4, polycation 5 has moderate 
antimicrobial efficiency that varies with bacterial strain. 
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Molecular polycation 3, polycation 5, and Cx-50 copolyoxetanes 1 share poor biocidal 
efficacy with short alkyl chain lengths. At longer chain lengths near the optimum C8-50, Cx-50 
copolyoxetanes 1 are not very sensitive to alkyl group chain length. This relative potency toward 
Gram(-) E. coli and P. aeruginosa and Gram(+) S. aureus differs little in the C6/C10-50 
compositional range is advantageous. The uniformly high antimicrobial effectiveness of C8-50 
may portend low MICs for a broad range of pathogenic bacteria. 
 
Killing Kinetics Assay. Rapid kill of pathogenic bacteria is of practical value and is important for 
developing model(s) of polycation biocidal action. Thirty years ago, Ikeda carried out pioneering 
research on antimicrobial effectiveness of several polycations.[26, 28] Since these studies, 
surprisingly little has been reported on polycation kill kinetics. Based on Ikeda‟s method, a kill 
kinetic assay was performed to determine the biocidal effectiveness of the most effective 
copolyoxetane (C8-50) as a function of time.  
Figure 3.4 shows bacterial kill over three hours for C8-50 at a concentration of 5 times 
MIC. Three separate experiments were done in triplicate yielding low standard deviations. The 
bacterial challenges were ~ 10
8
 cfu/ml Gram(-) E. coli and P. aeruginosa and Gram(+) S. aureus. 
Log reductions of 7 (0), 3.0 (0.18) and 5.0 (0.13) were obtained for S. aureus, E. coli and P. 
aeruginosa, respectively, at the end of 1 hour. 
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The kill kinetics study shows that the C8-50 kills >99% of the bacterial cells during the 
first hour. The order of MICs is S. aureus < E. coli << P. aeruginosa, From these MICs, it might 
be anticipated that P. aeruginosa would exhibit slower kill kinetics than either S aureus or E. coli 
and that E. coli would have the fastest kill kinetics. However, the order of rate of kill is S. aureus 
>> P. aeruginosa >> E. coli. This order must result from a nonlinear dependence of C8-50 
concentration on rate of kill. Choosing 5× MIC resulted in a C8-50 concentration of 125 µg/ml 
against P. aeruginosa. While for E. coli the concentration was only 20 µg/ml. 
 
 
Figure 3.4. Killing kinetic assays for (A) E. coli, (B) P. aeruginosa, and               
(C) S. aureus 
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Figure 3.4 shows that 100% kill, that is a 7 log reduction, 
for S. aureus was observed in 1 hr at 10 µg/ml (5× MIC). This rate 
may be compared with Ikeda‟s result for the polyacrylate 6, which 
is the only polymer polycation for which kill kinetics have been 
reported.[28] Polycation 6 has a relatively high MIC:[26, 99] 660-
1000 µg/ml for E. coli, 100-330 µg/ml for S. aureus and 660-1000 
µg/ml for P. aeruginosa. For comparing kill rates, the original data 
of Ikeda have been converted to log reduction of the original 
challenge (Table B1). From these data, a concentration of 29 µg/ml 6 against S. aureus gave a 
log reduction of 3.1 in 1 hour.[26] Considering that 29 µg/ml is at the most ~ 0.3 MIC,  the 3 log 
reduction/1h is noteworthy. However, the bacterial challenge was 10
5
 cfu/ml which is 3 log 
lower than those employed for testing C8-50.  
 
Kill kinetics for C8-50 may be compared with those recently obtained for the molecular 
polycation 3, designated CSA-13.[38]CSA-13 was tested at 10 times MIC (10 µg/ml) against a 
clinical isolate of vancomycin-resistant S. aureus. Kill rates were 3.8 log reduction/4 hr and 4.8 
log reduction/8 hr.[1, 38]For these tests the bacterial challenges were 3.2 x 10
8
 cfu/ml. This 
concentration is similar to those used for C12-43 which is 1.9 x 10
8
 cfu/ml. By comparison, 
C12-43 at 10x MIC (53 µg/ml) effects a log reduction of 3.6 against S. aureus  (ATCC-25904) 
at 1 hr while 3 effects a 3.2 log reduction in 3 hours.  
 
Finally, in view of the limited development of heuristics for bacterial kill rate, the kill 
rates for antibiotics are noted. Ciprofloxacin, ofloxacin, sparfloxacin and trovafloxacin were 
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tested against 2 strains of S. aureus.[111] For both ciprofloxacin and ofloxacin, at 8 times MIC 
(4 µg/ml), a log reduction of <2.5 was observed at the end of 2 hours for a starting inoculum of ~ 
10
6
 cfu/ml.  
 
Cytotoxicity for HFF and HDF cell lines. Cx-50 copolyoxetanes with x = 6, 8 and 10 carbon 
atoms were employed to investigate cytotoxicity toward mammalian cell lines as they were the 
most effective compositions with regard to antimicrobial activity. From Table 3.2 it is seen that 
among the Cx-50 copolyoxetanes, C6-50 has the least toxicity towards fibroblast cells (60,000 
µg/ml for HFF cells and 61000 µg/ml for HDF cells). Table 3.2 shows that toxicity towards 
fibroblast cells increases with increasing length of the alkyl chain from 6 to 10 carbon atoms. 
Even though C10-50 has relatively low values for EC50, i.e., 36000 µg/ml for HFF cells and 
37000 µg/ml for HDF cells, cytotoxicity is minimal considering bacterial MICs.  
 
 
Table 3.2. Cytotoxicity against HFFs, HDFs and RBCs as a function of the alkylammonium 
chain length of the Cx-50 copolyoxetanes. 
 
Copolyoxetane  EC50(µg/ml) HC50 (µg/ml) 
HFF HDF RBC 
C6-50 60000 61000 762 
C8-50 42000 41000 303 
C10-50 36000 37000 353 
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Selectivities. Selectivity, S, defined by Eq. 1 is a measure of the concentration required to lyse 
50% human cells (EC50) compared to the minimal concentration for inhibiting the growth of 
bacteria (MIC). High selectivities mean effective antimicrobial activity while minimizing effects 
on human cells. As a measure of cytotoxicity, selectivities provide an optimistic estimate of 
antibiotic effectiveness, as the MIC is typically 2-4 times lower than the minimal biocidal 
concentration, MBC.[99] Nevertheless, the measurement of selectivity provides a guide for 
potential use of antimicrobials as antibiotics.  
 
MIC
EC50S      Eq. 1   
 
The selectivities follow the EC50 trend with C6-50 and C8-50 being more selective 
towards human fibroblasts compared to bacterial cells than C10-50 (Table 3.3). The general 
trend of selectivity for Cx-50 copolyoxetanes is evident with an inverse dependence on the alkyl 
chain length. The absolute values for selectivities follow the order S. aureus (x=6, 22600 to 
x=10, 11000) > E. coli (x = 6, 9200 to x = 10, 5870) >> P. aeruginosa (x = 6, 1990 to x = 10, 
1500). The lower selectivities for P. aeruginosa stem from MICs that are 5-6 times higher than 
those for E. coli and S. aureus. For comparison, an evaluation of 3 yielded a relatively low MIC 
(4 µg/ml) for P. aeruginosa.[81] However, 3 has an HC50 of ~120 µg/ml for RBCs giving a 
selectivity of 30.[1] As noted previously in several studies on other antimicrobials, P. aeruginosa 
has an outer membrane permeability that is 12-100 times lower than that of other gram negative 
bacteria.[9] Hence, P. aeruginosa is known to be resistant to most antimicrobials.[7]  
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Hemolytic activity assay. Hemolytic assays were performed using relatively low Cx-50 
copolyoxetanes concentrations but at least 10 times the MIC for S. aureus. Percent lysis of 
human RBCs vs. Cx-50 concentration is shown in Figure 3.5. At the highest concentration tested, 
C6-50 has the lowest lysis (9 %) whereas C8-50 affects 20 % lysis. The modest trend for 
increasing lysis with increasing Cx-50 concentration indicates that the concentration affecting 
50% human RBC lysis (HC50) would be much higher than 50 µg/ml. To correlate with literature 
studies on antimicrobials, high concentrations (to 5000 µg/ml) Cx-50 copolyoxetanes with x = 6, 
8 and 10 were tested on RBCs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Percent lysis of RBCs as a function of concentration of the Cx-50 
copolyoxetanes. (A) C6-50, (B) C8-50, (C) C10-50, and (D) C12-50 
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These hemolytic assays with high concentrations confirmed the benign nature of the Cx-
50 copolyoxetane towards human RBCs (Figure 3.6). The C6-50 copolyoxetane was the least 
hemolytic with an HC50 of 762 µg/ml (Table 3.2). The potent antimicrobial C8-50 was the most 
hemolytic with an HC50 of 303 µg/ml. Selectivity, S, defined by Eq. 2 is a measure of the 
concentration required to lyse 50 % of red blood cells (HC50) compared to the minimal 
concentration for inhibiting the growth of bacteria (MIC). The RBC selectivity for C6-50 was 
high for the tested strains of bacteria. From Table 3.3 it is seen that the highest RBC selectivity 
of 283 has been observed against S. aureus for C6-50. 
 
MIC
HC50S                                                              Eq. 2 
 
Table 3.3. Selectivities for Cx-50 copolyoxetanes for RBCs, HFFs, and HDF 
Copolyoxetane E. coli S. aureus P. aeruginosa 
RBC HFF HDF RBC HFF HDF RBC HFF HDF 
C6-50 
 
114 9050 9200 283 22200 22600 25 1960 1990 
C8-50 
 
65 9330 9110 152 21000 20500 13 1760 1720 
C10-50 
 
56 5710 5870 107 11000 11000 15 1460 1500 
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Comparative antimicrobial effectiveness and cytotoxicity. 
The above results for Cx-m copolyoxetanes are compared with selected studies on 
molecular and macromolecular polycation antimicrobials in Table 3.4. The selected 
antimicrobials are optimum compositions from the cited references. The compositions follow an 
order that places those with highest selectivities toward the top of the table. Some judgment was 
exercised in this regard, as a given polycation may have variable antimicrobial effectiveness and 
cell selectivity depending on the tested organisms. 
 
 
Figure 3.6. Percent lysis of RBCs as a function of concentration of the Cx-50 copolyoxetanes 
for (A) C6-50, (B) C8-50 and (C) C10-50  
 
0
20
40
60
80
100
0 1000 2000 3000 4000 5000 6000
Concentration (µg/ml)
R
B
C
 l
y
s
is
(%
)
A
B
C
R
B
C
 l
y
s
is
(%
)
 88 
 
Phenylene ethynelene molecular polycation 7 has an HC50 of 88 µg/ml against human 
RBCs.[84] This molecular polycation has two primary alkylammonium functions per uncharged 
group, which is about double the linear charge density of the Cx-50 copolyoxetanes, but 
achieved with quaternary alkylammonium function. The selectivity for S. aureus (440) is 
somewhat greater than that found for C6-50 (283). On the other hand, 7 has relatively low 
selectivity for other cell lines tested (60 for 3T3; 70 for HepG2). This comparison shows how 
radically different structures such as 7 (molecular aromatic, primary amine, 2:1 charge per 
neutral group, two C-Br bonds)[84] and 8, C6-50, P[(C6-50)(ME2Ox)-50:50-5.7] (aliphatic, 
quat, 1:1 charge per neutral group) are both good antimicrobials with low cytotoxicity. This 
comparison emphasizes how little is understood about fundamental interactions of polycation 
antimicrobials with bacteria and human cells and how these interactions compare with those of 
AMPs. 
 
Like molecular polycation 7, 9 has primary alkylammonium functionality but is a low 
molecular weight polymethacrylamide (Table 3.4). Polymer 9 has an HC50 of 6400 µg/ml for 
human RBCs and an EC50 of 34 µg/ml 
for Hep2 cells.[69] This polymer without 
alkyl side chains on nitrogen has the 
least toxicity towards mammalian cells, 
while copolymers with a butyl or hexyl 
pendant group exhibit high cytoxicity. 
Copolymer 9-a with 49 mole % cationic charge has a comparable charge density and alkyl chain 
length to that of the C6-50 copolyoxetane. However, copolymer 9-a also has a low HC50 (<12 
O S
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µg/ml) compared to 762 µg/ml for C6-50. The selectivity of the hexyl copolymer 9-a for human 
RBCs compared to E. coli and S. aureus is 0.15 compared to 114 (E. coli) and 283 (S. aurerus) 
for C6-50. Once again the imperfect knowledge of polycation / cell interactions makes 
correlations difficult.  
 
The pyridinium methacrylate copolymers 10 have a similar charge density compared to 
the Cx-50 copolyoxetanes.[50] Copolymer 10 with butyl N-side chains has the least cytotoxicity 
towards human red blood cells (HC50 = 1709 µg/ml). However, relatively high MICs of 50 µg/ml 
(E. coli) and 30 µg/ml (B. subtilis) make the copolymer less selective (selectivity 34 for E. coli 
and 57 for B. subtilis ) toward human red blood cells compared to the microbes. Copolymers 10 
with hexyl and octyl side chain have HC50 values of 500 µg/ml and 450 µg/ml respectively. The 
relatively high MICs (40 µg/ml for R = hexyl and 100 µg/ml for R = octyl) leads to low 
selectivity values of ~ 12 and ~ 5 respectively for the copolymers compared to 114 for C6-50 and 
65 for C8-50 against E. coli.  
 
Methacrylate copolymers 11 with quaternary amine functionalized side group exhibit 
high HC50 (1200 µg/ml).[36] A high MIC (46 µg/ml) against a strain of E. coli leads to a low 
selectivity (26). Copolymer 11 with a 56 mole % quaternary ammonium charge has an HC50 of 
67 µg/ml that gives a selectivity of 2, while the lowest selectivity (65) for the Cx-50 
copolyoxetane series was for C8-50 (HC50 = 303 µg/ml). As above, subtle and as-yet not 
understood interactions for amphiphilic copolycation antimicrobials confound an easy 
interpretation of such comparisons.  
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Biocidal properties and cytotoxicity of polyoxanorbornenes 12 with alkyl pyridinium side 
chains gave a high HC50 of 4030 µg/ml (R = ethyl) but again, selectivity was low (20) because of 
relatively high MICs for  against E. coli and B. subtilis.[52] For R = hexyl, octyl and decyl side 
chains, polyoxanorbornenes 12 with a 10 kDa molecular weight had lower HC50 values (202 
µg/ml, <50 µg/ml, <50 µg/ml, respectively) compared to the corresponding 3 kDa polymer. 
Amphiphilic cationic polynorbornenes 13 with a molecular weight of 1.6 kDa was the least 
hemolytic towards human red blood cells compared to its other structural analogs.[34] Related 
structure 13 has an HC50 of >4000 µg/ml but rather poor antibacterial characteristics leads to low 
selectivities of  >20 (E. coli) and >13 (B. subtilis). 
 
Polyamine oxanorbornene copolymer 14 with a 50 mole percent of cationic charge gave 
an HC50 of 500 µg/ml against human red blood cells and a selectivity of 7 (E. coli) and 20 (S. 
aureus). Primary amine functionalized pyrimidine oligomer 15 has good antimicrobial properties 
with low MIC but it is also toxic towards human red blood cells (HC50 = 14 µg/ml) which gave a 
selectivity of 17.5.[39] 
 
 Finally, the biocidal effectiveness and cytotoxicity of 
an arylamide compound, PMX 30063, is noted.[112] The 
nature of PMX 30063 is not disclosed except for general 
structure 16. PMX 30063 is reported to have low toxicity toward mammalian cells with an HC50 
of >500 µg/ml, an EC50 of 430 µg/ml against 3T3 cells and 1031 µg/ml against HepG2 cells. A 
low MIC against S. aureus (1 µg/ml) leads to high selectivity for RBCs (>500), 3T3 cells (430) 
and HepG2 cells (1031 (HepG2). 
H
N
S
NH2
H
N
O O
n
 
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 91 
 
Conclusion 
 From previous studies we observed that increasing the linear charge density on C12-m 
copolyoxetanes resulted in optimum biocidal activity at a charge fraction of ~ 0.5.[99]Changing 
the alkyl chain length at the site of cationic charge in the copolyoxetane side chain had a 
profound influence on its antimicrobial property. The studies have shown that the Cx-50 
copolyoxetanes acquire an optimum antimicrobial characteristic when there are 8 carbon atoms 
on the site of cationic charge (x = 8). For x > 8, the biocidal efficacy decreases gradually. The 
antimicrobial properties of C6-50 is comparable to that of C8-50, while for x < 6, there is a 
sudden decrease in activity. Another key issue in side chain aggregation is the presence of the 
methyl groups at the side of the cationic charge (tertiary amine groups).   
The present investigation of cell compatibility has shown that the Cx-50 series have low 
toxicity towards human fibroblast cells and have high selectivities (E. coli, S. aureus and P. 
aeruginosa). The Cx-50 copolyoxetanes, particularly C6-50, exhibit low hemolysis of human red 
blood cells and have high selectivities. The water solubility of these polymers coupled with 
excellent antimicrobial behavior and cell compatibility makes these novel copolyoxetanes 
potential candidates for therapeutic applications.  
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Table 3.4. Comparison of cell toxicity and selectivity for polymeric and molecular polycations. 
 
 
Structure 
 
Description 
MIC (µg/ml) EC50 or 
HC50 
(µg/ml) 
Selectivity Ref 
7
Br
NH3Cl
Br
NH3Cl
 
Molecular phenylene 
ethynelene diammonium 
chloride 
 
 
0.21 µg/ml (S. 
aureus) 
 
88 µg/ml 
(RBC) 
 
12 µg/ml 
(3T3 
cells) 
 
14 µg/ml 
(HepG2 
cells) 
440 
 
 
 
60 
 
 
70 
[84] 
HO O O
H
OCH2CH2 O
OCH3 CH2
N
CH2
H
Br
1-mm
4
6
2
 
8 
C6-50 copolyoxetane 
Mn – 5.7 kDa 
m = 50 
2.7 µg/ml  
(S. aureus) 
 
31 µg/ml  
[P. aeruginosa]
 
 
 
6.7 µg/ml 
[[E. Coli]] 
762 µg/ml 
(RBC) 
 
60000 
µg/ml 
(HFF) 
 
61000 
µg/ml 
(HDF) 
283 
[25] 
[[114]] 
 
22200 
[1960] 
[[9050]] 
 
22600 
[1990] 
[[9200]] 
[99] 
 93 
 
9
O S
H
HN
NH3
O
O
Cl
n
 
Methacrylamide 
homopolymer with 
primary amine groups 
 
n = 17 
 
 
118 µg/ml (E. 
coli) 
 
 
 
10 µg/ml [S. 
aureus]  
~ 6400 
µg/ml 
(RBC) 
 
 
 34 µg/ml 
(Hep2) 
> 54  
[> 640] 
 
 
 
< 0.3 
 [3.4] 
[69] 
10 
N
R
O O
CH3
I
n n
 
Pyridinium methacrylate 
copolymers 
 
n = 50 
R = butyl group 
50 µg/ml 
(E. coli) 
 
 
30 µg/ml 
[B. subtlis] 
1709 
µg/ml 
(RBC) 
34 
[57] 
 
 
 
[50] 
11 
O S
H
O
R
O
N
O
O O
0.31
0.69 7
I
 
Methacrylate 
copolymers with a 
quaternary amine 
functionalized side 
group 
 
R = butyl group 
46 µg/ml (E. 
coli) 
1200 
µg/ml 
(RBC) 
26 [36] 
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12 
N
O
O O
N
R
CH2PhHC
Br
7
 
Polyoxanorbornene with 
alkyl pyridinium side 
chains 
 
R = ethyl group 
200 µg/ml (E. 
coli) 
 
 
200 µg/ml [B. 
subtilis] 
4030 
µg/ml 
(RBC) 
~ 20 
[~ 20] 
 
 
 
[52] 
13 
N
NH3
O O
n
CF3COO
 
Amphiphilic cationic 
polynorbornene 
derivatives 
200 µg/ml (E. 
coli) 
 
 
 
300 µg/ml [B. 
subtilis] 
> 4000 
µg/ml 
(RBC) 
> 20 
[> 13] 
 
 
 
 
[34] 
14
O
HCPh
N
O O
NH3
O
NO
O
CH2
R
0.50.5
CF3COO
 
Polyamine 
oxanorbornene 
copolymer 
 
 
R = propyl group 
75 µg/ml (E. 
coli) 
 
 
25 µg/ml [S. 
aureus] 
500 µg/ml 
(RBC) 
6.7 
[20] 
 
 
 
[113] 
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15
H2N
S
NH3C
H
N
NN
H
N
S
NH3C
NH2
O O
 
Pyrimidine oligomer 0.8 µg/ml (E. 
coli) 
 
0.8 µg/ml [B. 
subtilis] 
14 µg/ml 
(RBC) 
17.5 [39] 
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Chapter 4 
Effects of a Poly[(3,3-quaternary/PEG)-copolyoxetane] Antimicrobial on Pseudomonas 
aeruginosa biofilms 
 
ABSTRACT 
Effects of a polycation antimicrobial, poly[(3,3-quaternary/PEG)-copolyoxetane] (i.e. C8-50), on 
biomass and cell viability of Pseudomonas aeruginosa biofilms were investigated. Crystal violet 
(CV) staining assays demonstrate that C8-50 has no effect on adhesion of already established P. 
aeruginosa biofilms, but reduced biofilm formation by killing planktonic cells prior to 
attachment. For anti-adhesion assays, there is a noticeable reduction in biofilm mass at 
concentrations greater than MBC (~2× MIC). Viability studies show a substantial log reduction 
of 2.1 at MIC. These results suggest that C8-50 shows promise as a potential therapeutic. 
2 
Introduction  
 
Bacteria that are suspended and growing in a fluid environment live in a planktonic state 
while surface attached bacteria are sessile in a biofilm.[114] Being complex communities of 
surface and/or cell adhered microorganisms, biofilms fundamentally differ from their single 
celled planktonic counterparts. Biofilm growth occurs in sequential stages including i) transport 
of planktonic cells to a surface ii) initial attachment of planktonic cells (iii) formation of the 
extracellular polymeric substance, or exopolysaccharides,  EPS, matrix and microcolonies (iv) 
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formation of macrocolonies/ biofilm maturation and (v) dispersion, that is, release of 
bacteria.[15]  
The biofilm matrix of a fully hydrated biofilm is composed of water (50-90%) and EPS. 
This three dimensional matrix provides the means by which these bacterial communities are held 
together and forms a protective barrier for the adherent population.[115] The formation of 
bacterial biofilms aids survivability for a variety of intractable infections in humans.[116] The 
EPS is a mixture of polysaccharides, proteins, extracellular DNA and nucleic acids that have not 
been fully characterized but are believed to foster intercellular adhesion and surface attachment. 
[14, 117]Because of this matrix, bacteria living within a biofilm are less susceptible to 
environmental stresses, host immune responses, and antimicrobial agents.[12] Adherent bacteria 
are up to 1000 times more resistant than their planktonic counterparts.[14]  
 
This important virulence mechanism is estimated to comprise more than 80% of all 
human microbial infections.[116] Bacterial biofilms on medical devices are a steady source of 
infection as bacteria released from the biofilm invade surrounding tissues.[103]Another factor 
that aids in bacterial survival in biofilms is the presence of persistent cells that are completely 
resistant to antimicrobials that are effective against planktonic bacterial populations.[103]  
 
Pseudomonas aeruginosa is particularly virulent and persistent pathogen for 
immunocompromised patients, including burn patients, cystic fibrosis patients, and the elderly. 
P. aeruginosa contaminates contact lenses and indwelling medical devices such as catheters and 
is known to cause more than 200,000 hospital acquired infections in the United States annually. 
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[118] More than 80% of cystic fibrosis patients develop chronic lung P. aeruginosa biofilm 
infections that are difficult to eliminate with traditional antibiotics.[12, 13, 118]  
 
P. aeruginosa resistance has been shown for most antimicrobials, even planktonic 
populations.[7] The presence of added lipopolysaccharides and other mechanisms are believed to 
decrease the interaction of antimicrobials with the cell membrane. Among all Gram (-) bacteria, 
P. aeruginosa has an overall outer cell membrane permeability that is 12-100 times lower than E. 
coli.[8-10] Due to the presence of efficient efflux pumps, this bacteria has a low susceptibility 
toward antibiotics.[11] Inbuilt resistance coupled with the increased threat of multi-drug resistant 
strains is problematic as conventional treatments for P. aeruginosa  infections rely on long term 
multi- antibiotic treatment.[118]  
 
 A key component of immune function in a higher organism includes the ability to 
recognize and eradicate bacteria though naturally occurring antimicrobials. Antimicrobial 
peptides (AMPs) are an important element of the host immune system in many organisms 
including insects, plants, and animals.[103, 118]These antimicrobials do not demonstrate buildup 
of resistance because AMPs killing action is confined to attacking the cell wall 
membrane.[98]AMPs have chain structures with cationic moieties on one side and hydrophobic 
moieties on the opposite side leading to the term “facially amphiphilic”. This amphiphilic 
balance of naturally occurring AMP enables selective binding to bacterial cell membranes with 
no effect on mammalian cells.[51] AMP design is, therefore, an attractive model for synthetic 
mimics.[51]  
 
 99 
 
Isolating AMPs is complicated and cost prohibitive with regard to practical 
application.[103] Synthetic antimicrobial peptides have been synthesized which have proven 
even more potent than their naturally occurring counterparts. An emerging class of polycation 
antimicrobials take inspiration from these AMPs. These synthetic polycations promise economy 
via large scale production.[98] A  range of chemical structures have been reported with widely 
varying effectiveness against planktonic populations. 
 
  One subgroup of these polymer antimicrobials is the poly[(3,3-quaternary/PEG)-
copolyoxetanes]. The copolyoxetanes have quaternary alkyl  side chains and PEG-like ME2Ox 
side chains. The copolyoxetane used in this study is C8-50 where „50‟ is the mole percent of 
quaternary repeat units and „8‟ is quaternary alkyl chain length. 
 
 
 
 
 
 
MIC (minimum inhibitory concentration) assays have shown that C8-50 is a potent 
antimicrobial against several strains of bacteria.[99]MIC is defined as the lowest concentration 
of an antimicrobial that will inhibit visible growth of an organism after overnight incubation. 
MIC tests are a first step to assess antimicrobial effectiveness against planktonic (single cell) 
bacterial populations and determine feasibility as a potential therapeutic. 
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To further evaluate the antimicrobial effectiveness, a test against biofilms was carried 
out. The most potent copolyoxetane antimicrobial, C8-50, was chosen for testing against P. 
aeruginosa biofilms to determine biocidal efficacy. The first part of this study addresses whether 
C8-50 has an effect on adhesion of established biofilms and a second study addresses whether 
C8-50 can prevent biofilm formation. Finally, a study is presented that focuses on viability of 
established biofilms in the presence of C8-50.  
 
Experimental 
 
Determination on Minimum Bactericidal Concentration (MBC) MBC is defined as the 
concentration that kills the bacterial population (i.e. 99.99%). The MBC was determined 
according to previously reported methods.[99] 
 
Adhesion studies: biofilm detachment assay in 96 well plates. C8-50 was tested against pre-
existing biofilms as an assessment of effectiveness. Agar plates were streaked with P. 
aeruginosa (PA01) from a frozen stock culture at -70 
o
C and incubated at 37 
o
C for 18-24 hrs. 
From this plate, a single colony was collected and used to inoculate 6 ml of Luria broth. This 
culture solution was incubated for 24 hrs at 37 
o
C. A subculture was made by diluting it with M9 
mannitol medium to an OD600 of 0.02 and inoculating each cell with 100 µL of the subculture. 
Known protocols for growing biofilms in 96-well plates typically use Luria Broth.[12, 118]As 
noted earlier, C8-50 precipitates in this medium. Initial studies to optimize conditions for MIC 
tests established M9 mannitol as the medium of choice. The 96 well plates were covered with an 
air-permeable foil, put into a shallow glass dish lined with paper towels immersed in DI water, 
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and allowed to incubate at 37 °C for 24 hr. After this initial incubation, the biofilms contained 
within the 96 well plates were exposed to 40 µL of the C8-50 solutions prepared in M9 mannitol 
using a 2 fold dilution series. The initial stock solution concentration was at the solubility limit 
of C8-50 (400 mg/ml). Final C8-50 concentrations take into account the initial biofilm volume. 
An initial C8-50 concentration of 400 mg/ml is 114 mg/ml when diluted in the 96 well plates. 
For the P. aeruginosa controls, 40 µL of M9 mannitol media was added to keep volumes 
consistent with the biocidal challenge wells. Bacterial suspension, media, and no antimicrobial 
served as positive controls. Three wells contained bacterial suspension, media, and ethanol as 
negative controls. After subsequent 24 hr incubation at 37 °C, the cells were washed with a 
saline solution to remove nonadherent bacteria, stained with 0.1% crystal violet dye, incubated at 
room temperature for 20 min, washed with saline solution, and dried in air. Visual inspection 
qualitatively confirmed biofilm adherence because adsorbed dye correlated directly with biofilm 
density. Desorption of the dye into 30% acetic acid provided a semiquantitative measurement of 
optical density at 550 nm using a Versamax EXT microplate reader (Molecular Devices, 
Sunnyvale, CA). A minimum of four 96 well plates were used for each assay with at least three 
replicates of each C8-50 concentration per plate. Values in Figure 4.2 are the mean of twelve 
replicates with associated standard deviations. 
 
Biofilm formation assay: anti-biofilm adhesion studies. The same preparative procedure was 
used as described above with the exception that C8-50 solutions were introduced into the 96 well 
plates at the same time as the P. aeruginosa subculture. This assay was used to determine if C8-
50 would prevent biofilm formation. Values in Figure 4.5 are the mean of twelve replicates with 
associated standard deviations. 
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Viability Assays. Live cell counts (cfu) using standard plating techniques were used as a 
measure of viability. Because of the difficulty associated with removing live biofilms from 96 
well plates, biofilms were grown in 5 ml polystyrene test tubes. Agar plates were streaked with 
P. aeruginosa from a frozen stock culture at -70 
o
C and incubated at 37 
o
C for 18-24 hrs. From 
this plate, a single colony was collected and used to inoculate 6 ml of Luria broth. This culture 
solution was incubated for 18-24 hrs at 37 
o
C. A subculture was made by preparing a 1:100 
dilution in M9 mannitol medium and inoculating each test tube with 500 µL of the subculture. 
The preparative procedure used for the adhesion studies was scaled up 5× to account for the 
larger volume of the test tube compared to a 96 well plate. The test tubes were covered with an 
air-permeable foil, placed in a test tube rack within a shallow dish lined with paper towels 
soaked in DI water, covered loosely with aluminum foil, and allowed to incubate at 37 °C for 24 
hrs. Stock solutions of the C8-50 were prepared using M9 mannitol media then introduced to the 
individual test tubes at a volume of 200 µL and a final copolyoxetane with biofilm concentration 
at MIC, 5×MIC, and 10×MIC. These concentrations were chosen as they correspond to the 
earlier planktonic MIC studies and killing kinetic assays.[119]For the P. aeruginosa control, 200 
µL of M9 mannitol media was added to keep volumes consistent with the biocidal challenge test 
tubes.  
 
As there was no precedent to predict if the C8-50 would be effective against biofilms, a 
concentration of 1000× MIC was included. Each C8-50 test and the control consisted of four 
replicates. After 24 hr, each test tube was decanted, washed with saline three times to remove 
any unattached cells and media components and 1 ml saline was added. P. aeruginosa is a motile 
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organism that typically forms biofilms at the air-liquid interface.[120]Preliminary studies 
showed that vortexing alone did not adequately dislodge biofilms from the test tube sides. 
Therefore, the sides of the test tubes were manually scraped with sterile micropipette tips for 30 s 
to remove attached cells. Each test tube was recapped with a fresh sterile test tube caps and 
vortexed for 20 min each. Crystal violet (CV) staining of the polystyrene test tubes confirmed the 
complete removal of biofilm mass. From these initial 1 ml aliquots, 10-fold serial dilution series 
were plated on Luria agar in duplicate and incubated at 37 ºC for 24 hrs. The mean number of 
colonies were counted and compared with the mean control to obtain percent kill and log 
reductions according to Eq.1 and Eq. 2. 
 
Percent Kill Formula: 
                                           1001% 
control
sample
CFU
CFU
kill                            (Eq. 1) 
                                                         
 Log Reduction Formula:         
                                            Log Reduction 










1
log
sample
control
CFU
CFU
            (Eq. 2) 
                                                              
  
 
Results  
Biocidal activity of C8-50 against planktonic bacteria. C8-50 MIC for P. aeruginosa is 24 
μg/ml with bacterial challenges of ~ 108 cfu/ml. MBC is 48 μg/ml (2× MIC). Killing kinetic 
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studies at a concentration of 5× MIC showed C8-50 killed > 99.9% P. aeruginosa bacteria within 
the first hour. Log reductions were: 5.0, 5.2 and 5.5 at 1 hr, 2 hr, and 3 hr, respectively. [119] 
 
Adhesion Assays. To determine if C8-50 would eradicate established biofilms, crystal violet 
(CV) staining assays were performed. Visual inspection of the 96 well plates after CV staining 
showed little variance in color among the positive P. aeruginosa controls and the antimicrobial 
challenge wells (Figure 4.1) indicating that C8-50 has no effect on adhesion of pre-existing 
biofilms. Further analyses of CV staining assays using UV-visible spectroscopy demonstrated 
that C8-50 did not reduce the biomass of established biofilms regardless of concentrations 
employed (Figure 4.2).  
 A similar effect was shown when Kapoor tested several AMPs (LL-37 and Pexaganin) 
that did not reduce biomass of pre-existing biofilms. [118] With the exception of LB used as the 
medium rather than M9 mannitol, CV staining assay procedures were similar to C8-50. It should 
be mentioned that CV staining can be used to measure biomass removal, but not 
disinfection.[121] Although the researchers do not provide an explanation as to why AMPs did 
not reduce biofilm mass, the inability of both C8-50 and AMPs tested to reduce biomass could 
be the result of limited diffusion into the exopolysaccharide matrix. Also, it is known that 
cationic moieties in AMPs and their synthetic analogs bind to DNA in the extracellular 
matrix.[118] Reaction of the antimicrobials, in this case, C8-50 and AMPs, or sorption to the 
biofilm matrix components can hinder the ability of an antimicrobial to penetrate the cells within 
the biofilm.[122] 
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Figure 4.1. Representative 96 well plate for C8-50 adhesion assay 
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Figure 4.2. Effect of C8-50 antimicrobial on established P. aeruginosa biofilms 
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For comparison, Kapoor demonstrated that conventional antibiotic tobramycin had no 
effect on established P. aeruginosa (PA 14) biofilms at MIC (0.7 µg/ml) and a ~30% reduction 
at ~16× MIC [118]}. Consistent with the results shown above, P. aeruginosa biofilm matrix 
slows down the diffusion of the positively charged aminoglycoside antibiotics, like 
tobramycin.[115]Ciprofloxacin showed ~60% reduction in biofilms at values between MIC 
(0.1µg/ml) and ~31× MIC. Suci et al reported that ciprofloxacin penetration is significantly 
reduced in a P. aeruginosa biofilm.[123] Fluoroquinolone antibiotics, like ciprofloxacin, are one 
of the most effective classes of antibiotics used to treat P. aeruginosa biofilm infections. This 
suggests even though ciprofloxacin also demonstrates delayed diffusion, other factors must be 
involved in ciprofloxacin‟s removal efficacy.  
 
Kapoor has tested P. aeruginosa (PA 14) biofilms against a class of synthetic 
antimicrobial peptoids. Peptoids, i.e. oligo-N-substituted glycines, are isomers of peptides with 
side chains attached to the backbone nitrogen instead of the α-carbon. Most peptoids tested were 
able to reduce biofilms by ~40% at values near their MICs. The most effective peptoid, “Peptoid 
1”, H-(NLys-Nspe-Nspe)4-NH2 , having repeat units shown in Figure 4.3, reduced established P. 
aeruginosa biofilms ~ 60% at MIC (22.7 µg/ml). Being facially amphiphilic, Peptoid 1 allows 
for more effective biofilm detachment because additional stabilization can be provided by the 
presence of aromatic side chains along one side of the structure. This may allow for increased 
localization of cationic charge on the opposite side of the structure near the cell membrane; 
therefore, increased activity which may contribute to biofilm detachment. 
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Figure 4.3. Repeat units for Peptoid 1, H-(NLys-Nspe-Nspe)4-NH2  
 
Anti-adhesion Assays. To determine if C8-50 could be used to inhibit biofilm formation, a 
crystal violet (CV) staining assay was used. On visual inspection, wells with the highest 
concentration of C8-50 had a paler purple color signifying reduced biomass compared to the 
darker purple wells with lower concentration of C8-50 and the P. aeruginosa controls (Figure 
4.4).  
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Figure 4.4. Representative 96 well plate for C8-50 anti-adhesion 
assay 
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Subsequent analyses of CV staining assays using UV-visible spectroscopy measured whether 
C8-50 eliminated biofilms prior to formation.  Exact MIC values for C8-50 and their multipliers 
were not tested for the adhesion assays but were included in the expanded range tested (3.5 
µg/ml to 114 mg/ml). The protocol typically calls for a 6-8 dilution series of the initial stock 
solution.[12] To keep tested concentration values within a narrower rage, a 2 fold dilution series 
was chosen. This was done so it would be easier to establish a trend for C8-50 concentrations 
near the MIC (Figure 4.6). From Figures 4.5 and 4.6, it is evident that C8-50 kills planktonic 
bacteria that could eventually form biofilms as there is a noticeable reduction in biofilm mass at 
concentrations greater than 27.9 µg/ml, a concentration that approximates the MIC. That is, 
biofilm mass is markedly diminished at 55.8 µg/ml, a concentration slightly higher than 2 ×MIC.  
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Figure 4.5. Effect of C8-50 antimicrobial as a preventative to P. aeruginosa 
biofilm formation 
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 For comparison, ciprofloxacin had ~ 60% reduction in concentrations up to 4×MIC (0.4 
µg/ml) while tobramycin did not show a significant reduction in biofilm formation until 8×MIC 
(~70%, 5.6 µg/mL).[118] The MBC value for ciprofloxacin is ~ 4-8× MIC [124]while 
tobramycin  is ~ 2× MIC.[125]Peptoid 1 had a ~70% reduction in biomass at MIC and other 
tested peptoids were ~40%.[118] C8-50 has no effect on P. aeruginosa biofilms at MIC but a 
biomass reduction of ~80% at concentrations ~2× MIC (i.e. MBC) and above.  
 
 
 
Figure 4.6. Effect of C8-50 antimicrobial as a preventative to P. aeruginosa 
biofilm formation at concentration values near MIC to 5× MIC 
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Viability Studies. Adhesion and anti-adhesion (CV staining) assays provide an estimate of 
biomass but do not provide information on viability. Bacterial plating was employed to 
determine if C8-50 could kill P. aeruginosa biofilms. Bacterial biofilm challenges were ~ 10
6
 
cfu/ml (based on P. aeruginosa control samples). Cell viability studies show that C8-50 kills 
>99.2% of P. aeruginosa biofilms at MIC (24 µg/ml) and higher percentages at greater 
concentrations (Table 4.1 and Figure 4.7). These results demonstrate that although C8-50 has no 
effect on adhesion of pre-existing biofilms, adherent components in the biofilm show greatly 
reduced activity. Log reductions of 2.1, 3.3, 4.5, and 6.8 were obtained for MIC, 5× MIC, 10× 
MIC, and 1000× MIC, respectively, after 24 hrs (Figure 4.8).  
 
It is important to mention that previous killing kinetic studies on planktonic P. 
aeruginosa at a concentration of 5× MIC showed C8-50 killed > 99.9% bacteria within the first 
hour.[119]  C8-50 also killed  > 99.9% of P. aeruginosa biofilms, but the challenges were 10
6
 
cfu/ml compared to 10
8
 cfu/ml. For viability studies, a log reduction of 3.3 was shown after 24 hr 
compared to a log reduction of 5.0 at 1 hr for planktonic studies. Although viability test results 
are promising, it is evident that C8-50 was less effective in killing biofilms than in killing 
planktonic populations. As mentioned earlier, this could be a result of limited diffusion and, or, 
sorption into the biofilm matrix hindering the antimicrobial‟s ability to penetrate the cells within 
the biofilm.[122] In addition, the presence of efficient efflux pumps in P. aeruginosa  further 
complicates cell penetration in both biofilm and planktonic populations and, thus, antibiotic 
susceptibility.[11]  
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Figure 4.7. Representative agar plates for P. aeruginosa biofilm viability assays with C8-
50 (no
 
dilution) (A) P. aeruginosa (control), challenge concentration ~6.6 × 10
6
 cfu/ml 
(B) MIC (C) 5× MIC (D) 10× MIC  
 
 
Figure 4.8. Log reduction of  P. aeruginosa biofilms vs. C8-50 
concentration. MIC is 24 µg/ml. Antimicrobial exposure time is 24 hr. 
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Table 4.1. Percent kill and log reductions of P. aeruginosa biofilms (~ 10
6 
cfu/ml) at several      
C8-50 copolyoxetane concentrations 
 
C8-50 
Concentration 
(µg/ml) 
MIC 
Multiplier 
Percent (%) Kill Log 
Reduction 
24 1 >99.2 2.1 
120 5 >99.9 3.3 
240 10 >99.99 4.5 
24000 1000 100 6.8 
 
  
There is limited research on the effect of antimicrobial peptides, molecular polycations, 
and polymer antimicrobials on biofilm viability. Biofilms can be grown under a wide variety of 
conditions and the method employed will affect antimicrobial performance.[103]It is difficult to 
make a direct comparison between antimicrobials, but relevant studies are summarized below 
and in Table 4.2. 
 
 Kapoor tested peptoids, AMPs, and conventional antibiotics for viability at 
concentrations close to peptoid MIC values and MBC concentrations (~8× MIC). The initial P. 
aeruginosa (PA14) biofilm challenge was ~10
10
 cfu/ml (in Luria broth) compared to ~ 10
6
 
cfu/ml for C8-50 (M9 mannitol). Ciprofloxacin and tobramycin caused significant reductions in 
biofilms ~2 and ~1 log reductions but these values translate to 31× MIC and 8× MIC. AMPs 
tested (LL-37 and Pexaganin) had no effect. Peptoid-1 had a ~1 log reduction and 1-C134MER 
showed a roughly 2 log reduction (Table 4.2). It is suggested that 1-C134MER, repeat units in 
Figure 4.9, had greater biocidal activity against biofilms than Peptoid-1 and AMPs, due to the 
presence of a Ntridec which has a long tridecyl, surfactant, hydrophobic tail which can disturb 
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the hydrophobic extracellular matrix and cause increased penetration of antimicrobial into the 
biofilm matrix.[118] The long alkyl chain in C8-50 has a similar effect. 
 
Figure 4.9. Repeat units for 1-C134MER, H-Ntridec-Nlys-Nspe-Nspe-NLys-NH2[118] 
 
 
In another study, the molecular polycation ceragenin CSA-13 was tested for P. 
aeruginosa (PA01) biofilm viability and showed complete eradication at 32 µg/ml (7 log 
reduction, ~13xMIC, MIC 2.5 µg/ml). CSA-13 had comparable concentration effectiveness to 
ciprofloxacin against gram negative bacterial biofilms tested (7 log reduction, reported 
ciprofloxacin MIC much lower at 0.15 µg/ml; translates to 213×MIC).[103] C8-50 showed 
>99.99% kill (4.5 log reduction) at 10× MIC and complete eradication (100% kill, 6.8 log 
reduction) at 1000×MIC. The testing procedure for CSA-13 included growing biofilms using 
TSB (trypic soy broth) in a bioreactor where the procedure for C8-50 used M9 mannitol in 
polystyrene test tubes. Initial P. aeruginosa biofilm challenge for CSA-13 was ~10
8
 cfu/ml 
compared to ~ 10
6
 cfu/ml for C8-50. Antimicrobial solutions remained static for 72 hrs for the 
ceragenins before final cell counts compared to 24 hrs for C8-50.[103]  
 
NLys Nspe
H CH3
O
N
O
NH3
Br
N
O
Ntridec 
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The molecular, primary polyamine CSA-13[38] shares amphiphilic characteristics with 
C8-50. Polycation CSA-13 has a rather rigid structure that favors facile conjugation with 
negatively charged species on a bacterial membrane or in the biofilm EPS. Both structures have 
long alkyl chains that favor EPS matrix and cell penetration which further aids killing inside the 
biofilm. MIC for CSA-13 (2.5 µg/ml) is comparatively lower than C8-50 MIC (24µg/ml). Unlike 
C8-50 with a flexible oxetane backbone, it is apparent that, for CSA-13, unfavorable 
conformational changes are minimized while multiple cation-anion interactions are maximized. 
This also translates to higher log reductions for CSA-13 compared to C8-50. 
 
 
 
 
 
 
 
 
 
NH2OOH2N
N
H
O
H2N
H H
 
CSA-13[1] 
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Table 4.2. Log reductions for P. aeruginosa biofilm viability studies of polycations, peptoids, 
and conventional antibiotics. 
 
Antimic MIC  
(µg/ml) 
MIC 
Multiplier 
Challenge 
(cfu/ml) 
Log Reductions 
C8-50 24 1 10
6
 2.1 
5 10
6
 3.3 
10 10
6
 4.5 
1000 10
6
 6.8 
Peptoid-1[118] 22.7 1 10
10 
1 
1-C134MER[118] 10.4-20.8 1 10
10 
2 
Ciprofloxacin[118] 0.1 31 10
10
 2 
Tobramycin[118] 0.7 8 10
10
 1 
CSA-13[103] 2.5 ~13 10
8 
~7 
Ciprofloxacin[103] 0.15 213 10
8
 ~7 
 
Conclusion 
CV staining assays demonstrate that C8-50 has no measurable effect on adhesion of already 
established P. aeruginosa biofilms, but can prevent biofilm formation by killing planktonic cells. 
For anti-adhesion assays, there is a measurable reduction in biofilm mass at concentrations 
greater than ~2× MIC which shows that C8-50 can be used as a biofilm preventative at values 
around MBC. MIC values only apply to free floating planktonic environments and, it is apparent, 
cannot be easily translated to sessile communities. Viability studies show a substantial log 
reduction of 2.1 at MIC which is similar to the result for C134MER . Both antimicrobials possess 
long cationic tails that can easily penetrate into the EPS matrix and further facilitate killing 
inside the biofilm matrix. 
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Chapter 5 
Conclusion and Further Exploration 
 
 Water soluble P[(Cx-m)(ME2Ox)] copolyoxetanes have been studied with regard to 
antimicrobial effectiveness. These compositions are designated Cx-m, where x is the number of 
carbons in the quaternary group on the Cx side chain and m is the mole percent quaternary 
segment. The remaining mole percent is a segment containing a PEG-like side chain (Chapter 3, 
1). Chapters 1 and 2 explored solution antimicrobial effectiveness and human cell cytotoxicity of 
Cx-m copolyoxetanes as a function of amphiphilic balance, that is, the segment ratio of C12 to 
PEG.  The length of the quaternary pendant group, dodecyldimethylammonium butoxymethyl   
(x = 12) was kept constant while charge density (m) was altered. MIC decreased with increasing 
C12 mole percent, reaching a minimum in the range C12-43 to C12-60. Overall, C12-43 had 
consistently low MICs for the three tested pathogenic bacteria: (bacteria, MIC, μg/ml) E. coli (6), 
S. aureus (5) and P. aeruginosa (33). At 5× MIC against a challenge of 10
8
 cfu/ml, C12-43 kills 
≥ 99% S. aureus, E. coli and P. aeruginosa within 1 hr. C12-m copolyoxetane cytotoxicity 
toward human red blood cells, human dermal fibroblasts (HDFs), and human foreskin fibroblasts 
(HFFs) was low indicating good prospects for biocompatibility. The tunability of C12-m 
copolyoxetane compositions, effective antimicrobial behavior against Gram (+) and Gram (-) 
bacteria, and promising biocompatibility offered opportunities for further modification.   
In view of the sensitivity of biocidal potency to amphiphilic balance, optimization of Cx-
m copolyoxetanes was explored in Chapter 3 by varying the alkyl chain length (from x = 2 to 16) 
while keeping the mole ratio constant near the biocidal optimum for C12-m (m = 50). A 
systematic dependence of alkyl chain length and MIC was found. The most lethal antimicrobial 
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was C8-50 with MIC values of (bacteria, MIC, μg/ml) E. coli (4), S. aureus (2) and P. 
aeruginosa (24). 4 μg/ml, E. coli, 2 μg/ml, S. aureus and 24 μg/ml, P. aeruginosa.  Kill kinetics 
for C8-50 at 5 × MIC affected > 99% kill in 1 hour for a challenge of 10
8
 cfu/ml. Most notable is 
a log reduction of 7 for S. aureus at 1 hour. Cell cytoxicity studies on the three most effective 
antimicrobials (C6-50, C8-50, C10-50) also yielded favorable results.  
 Chapter 4 addressed the effect of C8-50, the most potent antimicrobial copolyoxetane, on 
biomass and viability of P. aeruginosa biofilms. Crystal violet (CV) staining assays 
demonstrated that C8-50 has no effect on adhesion of already established P. aeruginosa biofilms, 
but reduced biofilm formation by killing planktonic cells prior to attachment. For anti-adhesion 
assays, there was a clear reduction in biofilm mass at concentrations greater than the minimum 
biocidal concentration (MBC, ~2× MIC). Viability studies show a substantial log reduction of 
2.1 at MIC.  
P. aeruginosa biofilms are not fully eradicated at 10× MIC but there is 100% kill at 
1000× MIC. The 4.5 log reduction at 10× MIC suggests that MBC is much closer to the C8-50 
10× MIC concentration (240 µg/ml) than the 1000× MIC concentration (24000 µg/ml). The 
question of the exact MBC concentration remains unanswered and will be the subject of future 
studies. To broaden the scope of this study, future studies will include new strains (such as 
PA14) to see if results comparable to P. aeruginosa (PA01) are obtained. 
 There are a number of additional avenues for future research. Studies to ensure that 
bacteria do not build up a resistance to Cx-m copolyoxetanes are desirable to confirm prior 
studies on AMP-like models and other reported work.[84, 126] The logical choice for studies of 
bacterial resistance is C8-50 due to superior biocidal effectiveness. Common antibiotics and 
commercially available AMPs, e.g. magainin, would be used for controls.  
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 Exploration of permeation for model membranes would give a better understanding of 
mechanisms involved in bacterial activity. Dr. Yasuhara of Nara Institute of Science and 
Technology has shown that lipid membrane disruption can be visualized directly by fluorescent 
spectroscopy.[127]  A recently initiated collaboration with Dr. Yasuhara will provide evidence 
concerning the question as to whether the kill mechanism is primarily a surface initiated process. 
A more complete evaluation of copolyoxetane biological activity is necessary to 
determine antimicrobial efficacy. In-vitro antibiotic sensitivity testing can be performed using 
Kirby-Bauer antibiotic testing (KB testing) For KB testing, wafers having surface films of Cx-m 
copolyoxetanes would be employed.[128, 129] Bacteria of a known concentration are grown on 
agar plates and exposed to these wafers. As the Cx-m copolyoxetane diffuses from the perimeter 
of the disk, a zone of inhibition is established where bacteria are killed. Regions where bacteria 
cannot grow will occur around the wafer. This zone of inhibition is generally inversely 
proportional to the MIC (i.e. the lower the MIC, the greater the zone of inhibition). Thus, the 
extent of formation of the zone of inhibition is a measure of biocidal effectiveness. This 
qualitative test is useful and is expected to be sensitive to the concentration of the Cx-m 
copolyoxetane film on the disk.   
Moving ahead, evaluation of the copolyoxetane as an antimicrobial using in vivo testing 
is desirable. In vivo animal studies could include testing for skin/sensitivity with a view to 
topical therapeutic use or even gastrointestinal effects of Cx-m copolyoxetanes on mice 
populations for possible oral antibiotic applications. 
Kuroda‟s work[69, 126] has shown that block copolymers have much higher selectivity 
than random copolymers. It is possible to prepare block copolyoxetanes,[130] but it is not known 
whether the block copolyoxetane precursors to Cx-m systems can be made. If this is possible, 
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future work could explore whether the block copolymers would have even higher antimicrobial 
effectiveness compared to the random copolymer analogs. 
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Appendix A-1: 
1
H-NMR determination of BBOx-m copolymer ratios  
 
BBOx-42 is chosen to illustrate the analysis method in detail. A similar analysis was done for all 
BBOx-m copolyoxetanes. These ratios are compared with monomer feed ratios in Table 1.2.  
 
Figure A1 shows the 
1
H-NMR spectrum of BBOx-42 and P[(C12-43)(ME2Ox)-2.5]. 
Assignments: „a‟ = peaks for [-O-CH2(CH2)2CH2-Br], „b‟ = peak for [-CH3 from ME2Ox plus 
BBOx], „c‟ = peak for [-CH2(CH2)10CH3 for C12] and „d‟ = peaks for [-CH3 from ME2Ox plus 
C12]. 
 
All mole percents were determined as described below for BBOx-42. The 
1
H-NMR peak at 0.91 
ppm (Figure A1, b) corresponds to the 2-methyl group on each repeat unit, while the peaks at 
1.68 and 1.92 ppm (a) are the middle methylene groups, -O-CH2CH2CH2CH2-Br, in the BBOx 
side chain. Considering ME2Ox as „x‟ and BBOx as „y‟, Equation (1a) describes the relationship 
of these peak areas:  
 
y
yx
Area
Area
ppm
ppm
4
33
92.168.1
91.0 


     Equation (1a) 
 
Where Area1.68 - 1.92ppm = area of the peaks between 1.68 and 1.92 ppm, and Area0.91 ppm = area of 
the peak at 0.91 ppm. From Equation (1a) we obtain: 
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ppm
ppmppm
Area
AreaArea
y
x
92.168.1
92.168.191.0
3
34


                Equation (1b) 
 
From Equation (1b), a value for x:y is obtained. Using Equation (1c), the value of „1-m‟ is 
calculated and likewise the value of m is obtained. 
 
ppm
ppmppm
Area
AreaArea
yx
x
m
91.0
92.168.191.0
4
34
1



   Equation (1c) 
 
The integrals for the peaks at 0.91 ppm [-CH3 from ME2Ox plus BBOx] and 1.68 and 1.92 ppm  
[-O-CH2(CH2)2CH2-Br] are, respectively, 12.52 (= 3x+3y) and 7.04 (=4y). From Equation (1b), 
the value for x/y is 1.37. Similarly, from Equation (1c), the value of „1-m‟ is 0.58 and „m‟ is 
0.42. The composition of the copolyoxetane thus obtained is (BBOx-42).  The ratio of 
(BBOx)/(ME2Ox) determined by 
1
H-NMR (1:1.4) compared to the feed ratio of 1:2 indicates 
that BBOx is incorporated preferentially into the copolyoxetane.  
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Figure A1. 
1
H-NMR of A, BBOx-42 and B, C12-43, for the above chemical structures, 
alphabetical designations refer to hydrogen protons exclusively 
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Appendix A-2. Copolymer ratios for C12-m copolyoxetanes. 
 
C12-43 is chosen to describe the method of determining C12 mole percent in detail. A similar 
analysis was done for all C12-m copolyoxetanes to provide redundancy in the determination of 
mole% C12. The agreement with independently determined mole percent BBOx and C12 
provides confirmation of complete substitution. The copolymer ratios determined for BBOx-m 
(Table 1.2) and C12-m (Table 1.3) are combined in a Table A3 below for facile comparison.  
 
The method to determine substitution for C12-100 is described in this section. 
1
H-NMR spectroscopy was used to establish complete substitution of C-Br by C12 amine for 
every C12-m composition. This was ascertained by the absence of the BBOx peak at 1.9 ppm in 
every C12-m. As an example, Figure A1.1 provides the 
1
H-NMR spectrum for BBOx-42 and 
C12-43. The absence of the 1.9 ppm BBOx peak in the spectrum of C12-43 is evident. Also, the 
prominent peak “c” between 1.2 and 1.4 ppm due to (CH2)10 appears in the spectrum of C12-43 
(and every C12-m copolyoxetane). This peak is absent in the 
1
H-NMR spectrum of the BBOx 
precursor. 
 
 Details for the determination of the ME2Ox/C12 ratio for C12-m copolyoxetanes by 
1
H-NMR 
are now provided. The 
1
H-NMR peak at 0.82 ppm corresponds to -CH3 in the 2-position of each 
repeat unit plus the -CH3 group at the end of the quaternary alkyl chain. The peaks “c” between 
1.2 and 1.4 ppm are unique to the C12 quaternary side chain. These peaks are due to the 
following (bolded) protons: -CH2(CH2)10CH3. Considering ME2Ox as „x‟ and C12 as „y‟, 
Equation (2a) describes the relationship of these peak areas:  
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y
yx
Area
Area
ppm
ppm
20
63
4.12.1
82.0 


        Equation (2a) 
Where Area1.2-1.4 ppm = area of the peaks between 1.2 and 1.4 ppm, and Area0.82 ppm = area of the 
peak at 0.82 ppm. From Equation (2a) we obtain: 
     
ppm
ppmppm
Area
AreaArea
y
x
4.12.1
4.12.182.0
3
620


                                           Equation (2b) 
From Equation (2b), a value for x:y is obtained. Using Equation (2c), we calculate „1-m‟ and 
obtain m. 
 
ppmppm
ppmppm
AreaArea
AreaArea
yx
x
m
4.12.182.0
4.12.182.0
320
620
1






                           Equation (2c) 
 
The integrals for the peaks at 0.82 ppm [-CH3 from ME2Ox plus C12] and between 1.2 to 1.4 
ppm [-CH2(CH2)10CH3 for C12] are, respectively, 12.9 (= 3x+6y) and 25.96 (=20y). From 
Equation 2b, the value of x/y is 1.32. Similarly, from Equation 2c, the value of „1-m‟ is 0.57 and 
„m‟ is 0.43. The composition of the copolyoxetane thus obtained is C12-43.  
 
C12-100 does not have ME2Ox repeats. Putting x = 0, the R.H.S of Equation (2a) becomes 
(6y/20y) = 0.3, which gives us the theoretical ratio of the peak areas. The actual ratio of peak 
areas (Area0.82 ppm/Area1.2-1.4 ppm = 11.07/35.7 = 0.31) from 
1
H-NMR is given by the L.H.S of 
Equation 2a. The actual ratio of the hydrogen atoms obtained from 
1
H-NMR thus complies with 
the calculated ratio and hence the composition C12-100 is reconfirmed. 
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Appendix A-3. Calculation for determination of MIC per quarternary charge repeat unit 
 
For C12-14; 
Mn = 7870 g/mol, MIC (E. coli) = 0.3 mg/ml 
The MIC is converted to µmol/ml. 
MIC = (0.3 mg/ml)(mol/7870 g)(g/1000 mg)(10
6
 µmol/mol) = 0.0381 µmol/ml 
C12-14 contains 14% quaternary charge bearing moiety. 
MIC per quaternary charge repeat unit = 0.0381 µmol/ml (0.14) = 0.0053 µmol 
alkylammonium/ml. 
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Appendix A-4. FTIR spectrum (% transmittance) for (A) BBOx-42 and (B) C12-43 in 
acetonitrile. 
 
 
Figure A2. FTIR spectrum (% transmittance) for (A) BBOx-42 and (B) C12-43 in acetonitrile. 
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Appendix A-5. Luria broth solutions with (A) bacterial growth (turbid) and (B) no 
bacterial growth (clear). 
 
 
 
Figure A3. Luria broth solutions with (A) bacterial growth (turbid) and (B) no bacterial growth 
(clear). 
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Appendix A-6. Media formulation for P. aeruginosa and E. coli cultures. 
 
 
Table A1. Media formulation for P. aeruginosa and E. coli cultures. 
 
 
 
5X M9 Salt solution 
Constituent Amount (g/L) 
Na2HPO4 30 
KH2PO4 15 
NH4Cl 5 
CaCl2 0.015 
The above salt solution is diluted 5 times to prepare the final growth 
media. 
 
 
1X Mannitol media 
Constituent Volume in ml 
5X M9 salt solution 20 
Sterilized water 80 
MgSO4.7H2O (1M) 0.1 
Mannitol (20 wt%) 1 
Luria Broth 1 
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Appendix A-7. Tryptic Soy Broth (TSB) medium formulation for S. aureus cultures. 
 
Table A2. Tryptic Soy Broth (TSB) medium formulation for S. aureus cultures.  
Constituent Amount (g/L) 
Tryptone 20 
Dextrose 27.5 
NaCl 5 
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Appendix A-8. A comparison of mole ratios from 
1
H-NMR spectroscopy for BBOx-m 
(Table 1.2) and C12-m copolyoxetanes (Table 1.3).  
 
 
 
Table A3. A comparison of mole ratios from 
1
H-NMR spectroscopy for BBOx-m (Table 1.2) 
and C12-m copolyoxetanes (Table 1.3).  
 
BBOx/ME2Ox     
mole ratio 
C12/ME2Ox
  
mole ratio 
14:86 14/86 
25:75 26/74 
42:58 43/57 
50:50 50/50 
60:40 60/40 
87:13 87/13 
100:0
 
100:0 
 
Appendix A reprinted (adapted) with permission from Chakrabarty, S.; King, A.; Kurt, P.; 
Zhang, W.; Ohman, D. E.; Wood, L. F.; Lovelace,C.; Rao, R.; Wynne, K. J. Biomacromolecules 
2011, 12(3):757-69. Copyright (2011) American Chemical Society.  
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Appendix B-1. 
1
H-NMR analysis for P[(BBOx-50)(ME2Ox)] copolyoxetane. 
 
 
The 
1
H-NMR peak at 0.91 ppm corresponds to the -CH3 side chains on each repeat unit, 
while the peaks at 1.68 and 1.92 ppm are the middle methylene groups, -O-CH2CH2CH2CH2-Br, 
in the BBOx side chain. Considering ME2Ox as „x‟ and BBOx as „y‟, Equation 1a describes the 
relationship of these peak areas:  
 
y
yx
Area
Area
ppm
ppm
4
33
92.1,68.1
91.0 
     Equation (1a) 
Where Area1.68,1.92ppm = area of the peaks between 1.68 and 1.92 ppm, and Area0.91 ppm = area of 
the peak at 0.91 ppm. From Equation 1a we obtain: 
ppm
ppmppm
Area
AreaArea
y
x
92.1,68.1
92.1,68.191.0
3
34 
    Equation (1b) 
From Equation 1b, a value for x:y is obtained. Using Equation 1c, the value of „1-m‟ is 
calculated and likewise the value of m is obtained. 
ppm
ppmppm
Area
AreaArea
yx
x
m
91.0
92.1,68.191.0
4
34
1



   Equation (1c) 
 
The integrals for the peaks at 0.91 ppm [-CH3 from ME2Ox plus BBOx] and 1.68 and 
1.92 ppm  [-O-CH2(CH2)2CH2-Br] are, respectively, 15.65 (= 3x+3y) and 10.45 (=4y). From 
Equation 1b, the value for x/y is 0.996. Similarly, from Equation 1c, the value of „1-m‟ is 0.498 
and „m‟ is 0.501. The composition of the copolyoxetane thus obtained is P[(BBOx-
50)(ME2Ox)].  The ratio of (BBOx)/(ME2Ox) determined by 
1
H-NMR (1:1) compared to the 
feed ratio of 1:1.22 indicates that BBOx is incorporated preferentially into the copolyoxetane.  
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Appendix B-2. 
1
H-NMR analysis for Cx-50 copolyoxetanes. 
 
1
H-NMR spectroscopy was used to establish that substitution of C-Br by the amine was 
complete. This was ascertained by the absence of the characteristic BBOx peak at 2 ppm. The 
Cx/ME2Ox ratio for P[(C12-m)(ME2Ox)] copolyoxetanes was also determined by 
1
H-NMR. An 
example of 
1
H-NMR analysis of C8-50 copolyoxetane is as follows: The 
1
H-NMR peak at 0.91 
ppm corresponds to -CH3 side chains on the 2-position of each repeat unit plus the -CH3 group at 
the end of the quaternary alkyl chain. The peaks between 1.2 and 1.4 ppm are unique to the C8 
quaternary side chain. These peaks are due to the following (bolded) protons: -CH2(CH2)6CH3. 
Considering ME2Ox as „x‟ and C8 as „y‟, Equation 2a describes the relationship of these peak 
areas:  
y
yx
Area
Area
ppm
ppm
12
63
4.1,2.1
91.0 
        Equation (2a) 
 
Where Area1.2,1.4 ppm = area of the peaks between 1.2 and 1.4 ppm, and Area0.91 ppm = area of the 
peak at 0.91 ppm. From Equation (2a) we obtain: 
     
ppm
ppmppm
Area
AreaArea
y
x
4.1,2.1
4.1,2.191.0
3
612 
                                           Equation (2b) 
From Equation (2b), a value for x:y is obtained. Using Equation 3, we calculate „m‟ and obtain 
1-m. 
 
ppmppm
ppmppm
AreaArea
AreaArea
yx
x
m
4.1,2.191.0
4.1,2.191.0
312
612
1




                         Equation (2c) 
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Figure 3.1 shows the 
1
H-NMR spectrum of P[(BBOx)(ME2Ox)-50:50] and the C8-50. 
Here, „a‟ = peaks for [-O-CH2(CH2)2CH2-Br], „b‟ = peak for [-CH3 from ME2Ox plus BBOx], 
„c‟ = peak for [-CH2(CH2)10CH3 for C12] and „d‟ = peaks for [-CH3 from ME2Ox plus C12]. 
The integrals for the peaks at 0.91 ppm [-CH3 from ME2Ox plus C8] and between 1.2 to 
1.4 ppm [-CH2(CH2)6CH3 for C8] are, respectively, 13.08 (= 3x+6y) and 17.42 (=12y). From 
Equation 2b, the value of x/y is 1.00. Similarly, from Equation (2c), the value of „1-m‟ is 0.5 and 
m is 0.5. The composition of the copolyoxetane thus obtained is C8-50. The 
1
H-NMR analyses 
for the other substituted copolyoxetanes are also done and are listed in Table 1.2.  
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Appendix B-3. FTIR spectra (% transmittance) for (A) P[(ME2Ox)(BBOx)-50:50-5.7] and 
(B) C8-50 in acetonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The C-Br peak appears at 650 cm
-1
 for the precursor while no absorption peak is observed for the 
C8-50 copolyoxetane in the 515 – 690 cm-1 region, as expected for complete quaternization. 
 
Figure B1. FTIR spectra (% transmittance) for (A ) P[(ME2Ox)(BBOx)-50:50-
5.7] and (B) C8-50 in acetonitrile. 
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Appendix B-4. Comparing the log reductions of some common polycations against S. 
aureus. 
 
Table B1. Comparing the log reductions of some common polycations against S. aureus. 
Antimic MIC (MIC 
multiplier) 
(µg/ml) 
Challenge 
(cfu/ml) 
Log reduction 
1 hr 2 hr 3 hr 
  
4 hr 8 hr 
C8-50 2 (5) 10
7
 7 --- --- --- --- 
5 100-330 (0.3-0.09)  3.2 x 10
5
 3.1 5.5 --- --- --- 
CSA-13, [1] 1 (10) 3.2 x 10
8
 0.9 2.1 3.2 3.8 4.8 
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